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ACUTE LEUKEMIA
1
COMPARISON OF OUTCOME FOLLOWING ALLOGENEIC BMT WITH
CYCLOPHOSPHAMIDE- TOTAL BODY IRRADIATION (CYTBI) VERSUS
BUSULFAN-CYCLOPHOSPHAMIDE (BUCY) CONDITIONING REGIMENS
FOR AML IN FIRST REMISSION
Litzow, M.R.1,2; Bolwell, B.2; Camitta, B.2; Copelan, E.2; Gale, R.2;
Giralt, S.2; Keating, A.2; Klein, J.2; Lazarus, H.2; Et, A.2 1. Mayo
Clinic, Rochester, MN; 2. IBMTR, Milwaukee, WI
The optimal conditioning regimen for allogeneic BMT for
AML remains controversial. We analyzed the outcome of HLA-
matched related sibling allogeneic BMT for 381 patients (pts)
receiving the BuCy conditioning regimen and 200 pts receiving
the CyTBI regimen who underwent transplant between 1988 and
1996 for AML in ﬁrst remission. Only patients receiving fraction-
ated TBI doses of 11.25 Gy or greater were included. Graft versus
host disease (GVHD) prophylaxis was with cyclosporine alone or
combined with methotrexate. The two groups of pts were compa-
rable except for older age and more donors who were CMV posi-
tive in the BuCy group and more pts who had received more than
one cycle of chemotherapy to achieve ﬁrst remission and more pts
who had received hematopoietic growth factor post transplant in
the CyTBI group. In multivariate analysis, the risk of relapse post
transplant was signiﬁcantly higher in the BuCy group (RR=1.72)
(95% CI, 1.05, 2.81, p=0.031). However, treatment-related mor-
tality (TRM), leukemia-free survival (LFS), and overall survival
(OS) was not significantly different between the two groups.
11/371 evaluable pts in the BuCy group experienced a central
nervous system (CNS) relapse whereas 0/194 pts in the CyTBI
group suffered a CNS relapse (p=0.02). The incidence of VOD
was greater in the BuCy group (13%) than the CyTBI group (6%)
(p=0.009). Neutrophil recovery was faster by one day in the BuCy
group compared with the CyTBI group (p=0.03). The risk of
development of acute and chronic GVHD was similar between the
two groups. In conclusion, the use of CyTBI for conditioning pts
for HLA-matched related allo BMT showed a lower risk of relapse
compared to BuCy, but no difference in TRM, LFS, or OS.
2
INFORMATION TECHNOLOGY AS A STRATEGIC DECISION FOR DATA
DRIVEN PATIENT ACCRUAL.
Mullaly, K.; Quigley, J. LifeMetrix, McLean, VA
LifeMetrix, Incorporated believes that improving the pace of
clinical trials translates into savings for the health care system.
One strategy, aimed at streamlining the accrual process improves
efﬁciency, and decreases costs. Data mining the marriage of clini-
cal and claims data deﬁnes a patient population, to a high level of
detail, incorporating inclusion and exclusion criteria. Managing
clinical trials with data driven information allows for targeting a
deﬁnitive patient population, and pinpointing providers and their
location. Trials initiated without mined data, yield a high number
of extraneous investigator sites, and eliminates many potential
patients who are treated outside of an academic medical center.
These variables lead to higher costs, variable patient data quality
and questionable enrollment. Using information technology as a
strategy improves patient data quality, increases patient enroll-
ment, and lowers costs for the sponsor and providers. LifeMetrix,
Inc. data warehouse represents patient data from over 6 million
lives involving numerous therapeutic areas, throughout the USA
and Puerto Rico. LifeMetrix, Inc. data warehouse has multi-lay-
ered system security and encryption technology insuring patient
confidentiality. Patients are identified via detailed database
queries. Then clinical representatives from LifeMetrix, Inc. work
in conjunction with the sponsor to further the screening and
accrual process. LifeMetrix, Inc. data mining strategy has proved
effective in assisting patient enrollment in all phases of clinical tri-
als and for commercial and cooperative groups.
3
INTRAVENOUS FOLLOWED BY ORAL ITRACONAZOLE FOR THE
TREATMENT OF AMPHOTERICIN B-REFRACTORY INVASIVE PUL-
MONARY ASPERGILLOSIS IN PATIENTS WITH HAEMATOLOGICAL
MALIGNANCY
Prentice, H.1; Caillot, D.1 1. Royal Free and University College Medical
School (Royal Free Campus), London, United Kingdom; 2. CHU,
Dijon, France
In a multi-centre trial of itraconazole in 31 immunocompro-
mised patients with invasive pulmonary aspergillosis, a subset of
21 patients had previously failed therapy with intravenous (IV)
amphotericin B. In this subset, 2 patients previously received IV
amphotericin B for treatment of conﬁrmed infection, 12 patients
received IV amphotericin B for treatment of presumed infection
and 10 patients received IV amphotericin B for prophylaxis.
Patients were assigned to receive IV itraconazole for 2 weeks (days
1 and 2, 200 mg b.i.d.; days 3 to 14, 200 mg once daily). Patients
subsequently received oral itraconazole capsules (200 mg b.i.d.)
for 12 weeks. At the end of day 2, the plasma concentration of
itraconazole was greater than 250 ng/ml in all patients for whom
data were available (n = 12). Mean plasma concentrations of itra-
conazole continued to increase throughout the IV and oral treat-
ment periods. Overall, 11/21 (52%) patients had a complete
(24%) or partial (29%) response at their last assessment and 3 oth-
ers had stable disease. Of the 10 patients who completed the study
(received 2 weeks IV and 12 weeks oral itraconazole), 9 (90%) had
a complete (50%) or partial (40%) response. During IV itracona-
zole treatment, adverse events occurred in 18/21 (86%) patients (1
deﬁnitely and 6 possibly drug related) and, during oral treatment,
11/21 (52%) patients experienced adverse events (5 possibly drug
related). A high frequency of adverse events is expected in this
patient population. In conclusion, IV itraconazole rapidly achieves
adequate plasma concentration in patients with haematological
malignancy. IV itraconazole followed by oral itraconazole is an
effective and safe treatment for invasive pulmonary aspergillosis in
patients who have failed to respond to IV amphotericin B.
ALLOGENEIC (GENERAL)
4
BRAIN IMAGING ABNORMALITIES ASSOCIATED WITH BONE MAR-
ROW TRANSPLANT THROMBOTIC MICROANGIOPATHY IN PATIENTS
RECEIVING CYCLOSPORIN A OR FK506
Bartynski, W.S.2; Zeigler, Z.R.1; Spearman, M.P.2; Lin, L.2; Shad-
duck, R.K.1; Lister, J.1 1. Western Pennsylvania Cancer Institute, Pitts-
burgh, PA; 2. Department of Radiology, The Western Pennsylvania
Hospital, Pittsburgh, PA
Purpose: To assess clinical pararmeters and imaging features
associated with cortex and white matter brain lesions in patients
with Cyclosporin A (CsA) or FK506 neurotoxicity.
Methods: Twenty-four patients developed neurotoxicity while
receiving CsA or FK506. Clinical data and 52 imaging studies (32
CT, 19 MR) were retrospectively reviewed. Twenty-one allo-
geneic hematopoietic stem cell transplant (alloHSCT) patients
were conditioned with cyclophosphamide (Cy)and total body irra-
diation (TBI) (n=11) or BuCy2 (n=5), Cy-Thiotepa (n=4) or
BEAM (n=1). Three patients received CsA for treatment of aplas-
tic anemia.
Results: All brain lesions visualized by CT or MR imaging were
present in a watershed distribution in the cerebral hemmispheres.
Bone marrow transplant thrombotic microangiopathy (BMT-
TM), grade 2-4, was present in the 18 patients where peripheral
smears and LDH levels were obtained. In 11 alloHSCT patients
conditioned with Cy-TBI and 3 patients with aplastic anemia,
lesions developed within subcortical and deep white matter with
minimal if any recognizable cortex abnormality. In the 10
alloHSCT patients conditioned with chemotherapy (BuCy2, Cy-
Thiotepa or BEAM)lesions developed primarily in the cortex with
diminished but present white matter abnormality. Cortex
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enhancement was present in some of these lesions demonstrating
a unique stippled peripheral pattern. MR angiography was abnor-
mal in one patient demonstrating a string of beads pattern resem-
bling severe arterial spasm or arteritis.
Conclusion: The imaging appearance of brain lesions present in
CsA or FK506 neurotoxicity appears to depend upon the trans-
plantation conditioning regimen. Non HSCT patients or
alloHSCT patients conditioned with Cy-TBI develop primarily
white matter lesions. AlloHSCT patients conditioned with
chemotherapy develop a mixture of cortex and white matter
lesions. Watershed location, the presence of grade 2-4 BMT-TM
and an arteritis-like pattern at MR angiography suggest a vascular
cause for the brain lesions. Cortex abnormality may reﬂect direct
toxicity in the brain watershed regions.
5
A TRIAL USE OF LOW-DOSE LIPO PGE1 (EGLANDINTM) FOR THE
PREVENTION OF HEPATIC VENO-OCCLUSIVE DISEASE AFTER
HEMATOPOIETIC STEM CELL TRANSPLANTAION IN CHILDREN WITH
HEMATOLOGIC MALIGNANCIES
Cho, B.; Kim, D.; Lee, H.; Kim, S.; Chung, N.; Kim, C.; Kim, H.
Catholic Hemopoietic Stem Cell Transplantation Center, Seoul,
South Korea
In this study we tested the hypothesis that vasodilatation and
antithrombogenic effect in damaged vessels using low-dose Lipo
PGE1(EglandinTM, WelFide Korea Co., Ltd, Korea) might result
in increased sinusoidal blood flow and in decreased obstruction
and minimize the incidence or severity of hepatic veno-occlusive
disease (VOD). Children underwent hematopoietic stem cell
transplantation for hematologic malignancies were enrolled in this
study. Lipo PGE1 was begun one day prior to the start of condi-
tioning to day 30 after stem cell transplantation in continuous
intravenous infusion at a dose of 1 µg/kg/day (0.042 µg/kg/hr).
We evaluate the incidence and severity of hepatic VOD and the
toxicity of Lipo PGE1. From November 1999 to Jun 2000, 20
patients (M:F=15:5, median age 5 years) underwent hematopoietic
stem cell (5 matched sibling bone marrow, 4 autologous bone
marrow, 8 unrelated bone marrow, 3 unrelated cord blood) trans-
plantation for hematologic malignancies (9 ALL, 8 AML, 3 CML)
were enrolled in this study. There was no occurrence of VOD
within 30 day of transplant. Only one out of 20 patients was diag-
nosed as delayed VOD, easily controlled moderate form, on post-
transplant day 58. There was no toxicity attribute to Lipo PGE1.
This study suggest that prophylactic low-dose Lipo PGE1 may
decrease the incidence of VOD in patients treated for hematologic
malignancies by hematopoietic stem cell transplantation.
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ISOLATION OF LYMPHOID OR MYELOID CELLS FROM WHOLE
BLOOD FOR DNA EXTRACTION AND CHIMERIC ANALYSIS IN LESS
THAN 1 HOUR.
Clarke, E.1; Marciniak, R.1; Woodside, S.1; Eaves, A.C.2,3; Thomas,
T.1; Conneally, E.2,3 1. StemCell Technologies, Vancouver, BC, Canada;
2. Terry Fox Laboratory, Vancouver, BC, Canada; 3. Leukemia/BMT
Program, BC Cancer Agency, Vancouver, BC, Canada
Nonmyeloablative transplantation is an option for some patients
who would otherwise be ineligible for an allogeneic transplan-
tation due to age or co-morbidity. These transplants have a
reduced early treatment-related mortality but the complications of
GVHD and rejection remain significant. Decisions regarding
immunomodulation (withdrawal of immunosuppression or admin-
istration of DLI) are generally made on the basis of T-cell chi-
merism analysis. Since lymphoid and myeloid engraftment is
asynchronous, lineage speciﬁc chimerism is required. Methods to
isolate the cells include cell sorting or multi-step separation tech-
niques which are time consuming, have poor cellular recovery and
may not be routinely available. We describe a rapid one step pro-
cedure which combines the speciﬁcity of antibody mediated sepa-
ration with the ease of density gradient centrifugation to enrich
for lymphoid or myeloid cells directly from whole blood. The
blood is incubated with antibody complexes which cross-link
unwanted white blood cells to red cells thereby forming rosettes.
The sample is layered over a density media and centrifuged.
Rosettes pellet and the desired cells collect at the plasma medium
interface. In these experiments, the T-cell enrichment cocktail
contained anti-CD16, 19, 36, 56 and glycophorin A which result-
ed in purities of 94% and recoveries of 68% (n=3). Myeloid cell
purities of 93% (n=3) were achieved using antibodies against
CD3, 8, 19, 56 and glycophorin A however using ficoll (1.077
g/mL) density separation, cell recoveries were typically 5%. We
tested media formulations with different densities and determined
that a density of 1.085 (g/mL) significantly enhanced myeloid
recovery to 26%, thereby reducing the blood volume required for
PCR-based chimerism analyses. In summary, this technique yields
highly enriched lymphoid and myeloid cell populations for
chimerism analysis in less than 1 hour without specialized equip-
ment and thus facilitates decisions regarding immunomodulation
following non-myeloablative transplants.
7
COMMUNITY RESPIRATORY VIRAL INFECTIONS IN ADULT ALLO-
GENEIC BONE MARROW AND PERIPHERAL BLOOD STEM CELL
TRANSPLANT RECIPIENTS
Copland, M.1; Carman, W.F.2; Franklin, I.M.1; Holyoake, T.L.1;
McQuaker, G.1; Jones, B.L.3; Parker, A.N.1 1. BMT Unit, Glasgow
Royal Inﬁrmary, Glasgow, United Kingdom; 2. Regional Virus Labo-
ratory, Gartnavel General Hospital, Glasgow, United Kingdom; 3.
Dept of Microbiology, Glasgow Royal Infirmary, Glasgow, United
Kingdom
Viral pneumonia is an important cause of morbidity and
mortality in patients undergoing allogeneic stem cell trans-
plantation. Viral pathogens such as respiratory syncytial virus
(RSV), influenza A and B (Flu A & B), parainfluenza (Paraflu)
and adenovirus are emerging as significant causes of upper
and lower respiratory tract infections (Clin Inf Dis
1996;22:778-82). A retrospective analysis of the incidence of
community respiratory viral infections in our population was
carried out for the 72 allogeneic BM and PBSC transplants
performed on 70 patients between January 1997 and Decem-
ber 1999. RSV, Flu A & B, Paraflu, adenovirus and picor-
navirus were detected using direct immunofluorescence test-
ing of nasopharyngeal aspirate or bronchoalveolar lavage fluid
as clinically indicated. The overall incidence of proven com-
munity respiratory viral infection was 26% in the first year
post allograft (19 of 72 transplants). There were 9 cases of
RSV (48%), 4 of Flu A (21%), 1 of Flu B (5%), 3 of Paraflu
III (16%), 1 of adenovirus (5%) and 1 of picornavirus (5%). In
13/19 infective episodes (68%), patients had lower respiratory
tract signs on examination and 7 of these patients had chest
X-ray changes. Of this group, 9 were treated with nebulised
ribavirin and 4 went on to receive IV ribavirin, one received
zanamivir and amantidine and three had no specific antiviral
therapy. Of the six patients with upper respiratory signs only,
three received specific anti-viral therapy with nebulised rib-
avirin. Overall of the 19 proven infections, 12 patients made a
full recovery, 2 died of RSV pneumonitis, 2 died of superim-
posed infection and 3 died of unrelated causes. 17/19 (89%)
viral infections occurred between October and February. In
conclusion, community respiratory tract infections are a sig-
nificant cause of morbidity and mortality in adult allogeneic
BMT and PBSCT patients and early diagnosis and specific
antiviral therapy are vital.
8
HEMOLYTIC-UREMIC SYNDROME RELATED TO ALLOGENEIC BLOOD
AND MARROW TRANSPLANTATION: CLINICAL OUTCOME IN 25 CASES
Daly, A.; Hasegawa, W.; Loach, D.; Tejpar, I.; Lipton, J.; Messner,
H.; Kiss, T. Princess Margaret Hospital, Toronto, ON, Canada
The goal of this study was to examine the outcome of and fac-
tors associated with the development of transplant-associated
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HUS. Only charts of patients who underwent plasma-exchange as
management of this syndrome were reviewed. HUS was deﬁned as
the presence of microangiopathic hemolysis and renal failure. 25
patients transplanted between November 1992 and July 1999 were
included.
The median age was 39 years (range 18-55). 12 were female. 12
were transplanted from unrelated donors. Diagnoses were ALL
(6), AML (6), CML (5), MDS (4), multiple myeloma (3) and aplas-
tic anemia (1). 10 patients had advanced disease. Conditioning
consisted of Cytarabine/cyclophosphamide/TBI (2), Cy/TBI (19)
and Bu/Cy (4). 24 patients received cyclosporine for GVHD pro-
phylaxis. 15 patients developed acute GVHD greater than grade I,
all of whom required treatment with ≥2 mg/kg Solumedrol or
equivalent steroids. 16/24 transplants involved patients or donors
who were CMV positive, reactivation occurred in 10 cases.
HUS developed at a median of 27 days (range 17-484). Patients
received a median of 10 plasma-exchange treatments (range 2-43).
The median survival following diagnosis was 28 days (range 15-
502). Only 1 patient remains alive on dialysis at 502 days. Median
survival from transplant was 66 days (range 32-733). At time of
death 15 patients had GVHD and 23 were on immunosuppres-
sion. 16 had active HUS at time of death. Causes of death were
GVHD (7), multi-organ failure (7), infection (4), bleeding (4),
pulmonary embolism (1) and unknown (1). 12 had significant
infections at time of death, including bacterial (6), fungal (5) and
CMV (3) infections.
Transplant-related HUS is associated with high mortality and
responds poorly to treatment. Most patients received radiation for
conditioning, cyclosporine prophylaxis and high-dose steroids for
GVHD treatment. Patients frequently had serious infections at
time of death.
9
RISK OF CYTOMEGALOVIRUS INFECTION IN PEDIATRIC ALLOGENEIC
STEM CELL TRANSPLANTS
Heilmann, C.; Haastrup, E.; Baekgaard, H.; Müller, K.; Jacobsen, N.
Rigshospitalet, Copenhagen, Denmark
Since March 1993 we have adopted a preemptive treatment
strategy for CMV infection. The aim of this study was to examine
prospectively the impact of CMV infection and disease among
children undergoing BMT.
Methods: 111 transplants were performed before Jan. 2000.
The median age was 9 years. Donors were HLA-id siblings
(n:38), other family (n:16) or matched unrelated (n:57). Seven-
ty-nine children were transplanted for clonal diseases, 16 for
non malignant haematologic diseases and 16 for immunodefi-
ciency or storage disease. CMV antigenaemia was evaluated by
detection pp65 phosphor protein in blood leucocytes or by
blood culture. Prophylaxis against CMV reactivation consisted
of high-dose acyclovir IV followed by oral acyclovir. The pre-
emptive strategy involved weekly examination of CMV in blood
to day 90. In case of a positive test treatment with gancyclovir
was given.
Results: In 19 children (17%) CMV was found in the blood in
further four children blood tests were negative but CMV was
suspected to be clinically significant on the basis of a positive
test from other sites. In two patients (8%) CMV was detected
in spite of the use of filtered blood and a seronegative donor
and recipient. CMV antigen was found in 30% of MUD trans-
plants but in only 11% of family donor transplants. The inci-
dence of a positive CMV test did not differ between patients
experiencing aGvHD and those who did not. Signs of CMV
disease occurred in 22 patients. CMV disease was not the direct
cause of death in any of the patients but may have been a con-
tributing factor in three.
In conclusion, the combination of high dose acyclovir prophy-
laxis and a preemptive treatment strategy based on regular exami-
nation of the blood for CMV the ﬁrst three months after trans-
plant seems to be effective in preventing CMV disease and CMV
related death in allotransplanted children.
10
USE OF MMF AND CYCLOSPORINE WITH PERIPHERAL BLOOD STEM
CELL (PBSC) INFUSION TO TREAT LATE GRAFT FAILURE
Khan, S.P.; Krance, R.A.; Brenner, M.K.; Heslop, H.E.; Kuehnle, I.;
Alcoser, P.W.; Rodgers, C.C. Baylor College of Medicine, Houston, TX
Late graft failure has been reported in patients (pts) with aplastic
anemia (AA). Treatment has usually consisted of intensive condi-
tioning followed by a second transplant. Two children, one with
AA and one with sickle cell disease (SCD) presented with late graft
failure following allogeneic BMT from HLA matched siblings.
Pt # 1 with AA had normal counts, normal bone marrow cellu-
larity and 100 % donor chimerism post transplant at day +28 and
+100. Cyclosporin (CSA) was discontinued 8 months post BMT.
At day +842 thrombocytopenia ( plts 35k) and neutropenia (ANC
630) appeared. Viral studies (CMV, EBV and Parvo virus) were
negative and bone marrow biopsy showed 20% cellularity with
mixed chimerism (70 % donor cells). Pt 2 with SCD, (20% hemo-
globin S post transplant) remained a mixed chimera at day +18
and day + 160 with 88 % and 80 % donor cells. At day +630,
thrombocytopenia ( plts 23k) and neutropenia (ANC 200)
occurred. Viral studies were negative. Bone marrow chimerism
studies demonstrated 50% donor cells. Pts were treated with
MMF 15 mg per kg BID (Day 0-28), CSA 6mg per kg BID po(day
−2), and PBSC infusion from the original donors. The CD 34
dose was 2.394x 10x6/kg for pt #1 and 3.44x 10x6/kg for pt # 2.
Pts recovered normal WBC, hemoglobin, and platelets in 2 weeks
following PBSC infusion. Bone marrow for pt # 1(day +165)
showed 94% and 100% donor cells at day +28 and +60; bone mar-
row for pt # 2 (day +70) showed 97.5% donor cells at day +28.
Both patients receive CSA without GVHD.
We conclude that immunosuppression with PBSC infusion may
be effective therapy for patients with hematological disorders who
have evidence of late graft failure but who remain mixed chimeras.
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OMISSION OF DAY +11 METHOTREXATE FOR GRAFT-VERSUS-HOST
DISEASE PROPHYLAXIS AFTER ALLOGENIC BMT INCREASES THE
RISK OF SEVERE ACUTE GRAFT-VERSUS-HOST DISEASE
Kumar, S.; Chen, M.G.; Gastineau, D.A.; Gertz, M.A.; Inwards, D.J.;
Lacy, M.Q.; Tefferi, A.; Litzow, M.R. Mayo Clinic, Rochester, MN
Background: The combination of cyclosporine (CSA) and short-
course methotrexate (MTX) is the most commonly used regimen
for graft-versus-host disease (GVHD) prophylaxis after allogenic
BMT . It is unclear if omission of the day +11 dose of MTX, often
due to severe mucositis and hepatic or renal dysfunction, will
increase the risk for development of acute or chronic GVHD.
Methods and Materials: A review of 135 patients who received
CSA-MTX prophylaxis after allogeneic BMT at our institution
between 1982 and 1997 was done to examine this question.
Patients who received less than three doses of MTX and those who
died before day +11 were excluded. Of the 123 eligible transplants,
84 patients received all four doses and 39 received three doses.
Results: 23/39 (59%) patients receiving 3 doses of MTX devel-
oped acute GVHD (grade 1-4) compared to 57/84 (68%) receiv-
ing 4 doses (p=0.33). 15/39 (39%) patients in the three-dose group
compared to 31/84 in the four doses group (37%) developed
chronic GVHD (p=0.87). However, the 3-dose group was more
likely to develop grade 3-4 acute GVHD (12/39; 31%) compared
to the 4-dose group (12/84; 14%), p=0.03. This higher risk per-
sisted even after excluding the patients who had MTX held due to
organ dysfunction. The relapse free survival was similar. The
overall survival was less for the 3-dose group, however. This was
mostly secondary to early mortality in the subgroup of patients
who had MTX withheld due to hepatic or renal dysfunction and is
likely a consequence of transplant related toxicity.
Conclusion: Omission of day +11 methotrexate did not increase
the overall rate of acute or chronic GVHD, but appeared to
increase the risk for severe acute GVHD (grades 3-4). Therefore,
every attempt should be made to complete the full course of
MTX doses.
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ROLE OF ALLOGENEIC BONE MARROW TRANSPLANTATION AS
POSTREMISSION THERAPY IN ADULT PATIENTS WITH HIGH-RISK
ACUTE LYMPHOBLASTIC LEUKEMIA IN FIRST REMISSION: A SINGLE
CENTER EXPERIENCE (1994-1999)
Lee, S.; Min, C.; Kim, D.; Lee, J.; Min, W.; Kim, C. Catholic Hemo-
poietic Stem Cell Transplantation Center, The Catholic University of
Korea, Seoul, South Korea
Optimal postremission therapy remains controversial in adults
with ALL. In this study, we compared allo-BMT with auto-
PBSCT using the result of the HLA typing as a random alloca-
tion. Patients were eligible if they were in CR1 and had either:
adverse cytogenetics (Ph+, 11q23), age > 30 years, time-to-CR1 >
4 weeks or presenting WBC > 30,000/µL. From July 1994 to June
1999, 50 consecutive adults with high-risk ALL underwent HLA-
matched allo-BMT (n=31) or auto-PBSCT (n=19) at this center.
There were 27 males and 23 females with median age 30 (range,
15-43) years. The distribution of phenotype was as follows: L1
(n=29), L2 (n=21), precursor B (n=36), T (n=9), myeloid marker
coexpression (n=5). Adverse cytogenetics at diagnosis were shown
in 23 (46.0%) cases. Of these patients, 19 (allo-BMT 10, auto-
PBSCT 9) had the Ph chromosome. All pretransplant characteris-
tics were well balanced between these two groups. Most patients
were treated with TBI containing regimen as part of the condi-
tioning. With a median follow-up of 27 months in both groups,
there was no significant difference in overall survival between
these two groups (72.4% vs 62.7%, p>0.05). However, the relapse
rates were significantly different between allo-BMT and auto-
PBSCT groups (25.8% vs 52.6%, p=0.05) and allo-BMT had a
trend toward better DFS (70.6% vs 42.1%, p=0.07). None of the
pretransplant characteristics significantly affected outcome after
transplantation, except adverse cytogenetics. Prognosis of ALL
with Ph+ or 11q23 was significantly poorer than that of the
remaining high-risk ALL patients (p<0.01). We conclude that
allo-BMT appears to be more effective than auto-PBSCT in pro-
longing initial CR for high-risk ALL patients. Prospective studies
addressing additional clinical variables are needed to guide clinical
decision making about transplant choices for adult patients with
ALL. New therapeutic strategies for the management of ALL
with adverse cytogenetics will be also required.
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A NATIONAL SIBLING DONOR CORD BLOOD (SDCB) PROGRAM FOR
CHILDREN WITH MALIGNANT AND NON-MALIGNANT DISEASE
Lubin, B.; Tractenberg, E.; Walters, M.; Smith, R.; Dekovic, F.;
Epstein, J.; Scarpetra, A.; Reed, W. Childrens Hospital Oakland
Research Institute, Oakland
CB has proven to be an important resource for hematopoetic
stem cell (HSCs) transplantation (TX). Besides its immediate
availability and absence of risk to the donor, even without a com-
plete HLA match, CB TX are associated with less acute and
chronic GVHD than bone marrow or peripheral blood TX per-
formed under similar conditions. While delayed engraftment and
limited numbers of HSC precursors may limit CB use, as these
obstacles and overcome, the use of CB as an alternative HSCs will
increase. In response to the success of CB TX, private for-proﬁt
(aurologous) and public (unrelated) CB banks have developed
throughout the world. We present our experience establishing the
first NIH supported National SDCB program. Our program
offers free facilitation of CB collection to families who currently
have a child that could potentially beneﬁt from a TX. The pro-
gram provides individual case management services. In its ﬁrst 2
years, 405 CBs in 36 states were collected, 80% cam frEom com-
munity hospitals, 85% contained a nucleated cell count of
2.5X107 /kg recipient weight and 3% were bacterially contaminat-
ed. Potential recipients had malignant or non-malignant hemato-
logic diseases. Molecular HLA typing indicated that 25% of the
CBs were 6/6 HLA matched with the recipient and an additional
15% were 4-5/6 HLA matched. In the 9 TX performed during
the ﬁrst two years of operation, all engrafted and non e developed
signiﬁcant GVHD. 7 patients with sickle cell, 1 with myelodyspla-
sia, 1 with aplastic anemia and 3 with thalassemia appear to be
cured of their diseases. These results demonstrate that quality CB
can be collected at remote sites using our case management model
and that a national SDCB resource can be used to conduct
prospective clinical trials of SDCB TX, especially in children with
hemoglobinopathies.
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ALLOGENEIC PERIPHERAL PROGENITOR CELLS TRANSPLANTATION
IN HEMATOLOGICAL DISEASES: INCIDENCE OF GVHD. REPORT FROM
A SINGLE INSTITUTION
Milone, G.A.; Martinez Rolón, J.; Fernandez, I.; Desmery, P.; Juni,
M.; Pavlovsky, S. Fundaleu, Buenos Aires, Argentina
We report the results from 16 patients (pts) with hematological
diseases (7 acute leukemias, 7 chronic leukemias, 1 aplastic anemia
and 1 lymphoblastic lymphoma) receiving allogeneic peripheral
blood progenitor cells transplantation. Median age: 29 years
(range 13/50); gender male 11, female 5. The median time from
diagnosis to transplant was 19 months (range 2-64). All donors
were mobilized with G-CSF 10 mcg/kg/daily until collection of
progenitor cells on days 5 to 7. The median of CD34+ cells col-
lected was 10.6x106/kg (range 3.3-24.3). The conditioning regi-
mens used were busulphan/cyclophosphamide in leukemias and
lymphoma, and cyclophosphamide alone in aplastic anemia. Graft
vs. Host Disease (GVHD) prophylaxis consists in 4 doses of
methotrexate plus cyclosporine for 180 days in addition to 4 doses
of gammaglobulin 400 mg/kg. aGVHD was observed in 8 pts
(50%); grade I: 4 pts; grade III: 3 pts and grade IV: 1 pt. The
median day of onset was 31 days.
Chronic GVHD was observed in 10 pts (67%): in 6 pts was
localized and in 4 was extensive. All pts resolved GVHD with
treatment (steroids alone in mild cases and steroids plus thalido-
mide in severe cases) with the only exception of the patient with
grade IV who died of the disease. aGVHD was similar as pub-
lished on the literature with the use of bone marrow, with a
greater incidence of chronic GVHD. Patients who presented
chronic GVHD were treated with at least two schemas, most of
them were refractory to steroids and responded with the addition
of a second drug. With a long follow-up most of these patients
repeated the GVHD episode. For the presentation we will update
another 14 patients with at least more than 6 months of follow-up.
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ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PATIENTS
WITH GOOD-RISK LEUKEMIAS—EARLY TRANSPLANTATION RELATED
MORTALITY AND SURVIVAL RATE—A SINGLE CENTER STUDY
Mitsui, H.; Kamae, T.; Masaie, H.; Taniguchi, Y.; Karasuno, T.;
Nakamura, H.; Hiraoka, A. Osaka Medical Center for Cancer and
Cardiovascular Diseases, Osaka, Japan
Purpose: The group of good-risk leukemias includes acute
leukemias in the ﬁrst complete remission and chronic myelogenous
leukemia (CML) in the ﬁrst chronic phase. Favorable prognosis of
allogeneic bone marrow transplantation (ABMT) is expected for
this group. The early transplantation-related mortality (TRM)
(mortality within 100 days after BMT) and survival of this group
was examined.
Patients and Methods: Between 1985 and 2000, 166 patients with
good-risk leukemias received ABMT at The Osaka Medical Center
for Cancer and Cardiovascular Diseases. Fifty patients were with
acute nonlymphocytic leukemia (ANLL), 32 patients with acute
lymphocytic leukemia (ALL), and 84 patients with CML. One
hundred and twenty-seven patients received related -BMT (R-
BMT), the rest 39 patients received unrelated-BMT (U-BMT).
Results: 1) Overall early TRM was 9.0% (15/166 cases). For
each disease, early TRM was 10.0% for ANLL, 12.5% for ALL,
and 7.1% for CML. Among R-BMT patients, early TRM was
7.9% for all, 6.8% for ANLL, 11.1% for ALL, and 7.1% for
CML. 2) Disease free survival at 5 years (5-year DFS) was 65.8%
for ANLL, 52.7% for ALL, and 76.8% for CML. Among R-BMT
patients, 5-year DFS was 71.0% for ANLL, 58.8% for ALL, and
70.9% for CML. 3) Early TRM for each period was 17.1% for
1985-1988, 4.7% for 1989-1992, 10.4% for 1993-1996 (U-BMT
was started in 1993), and 5.0% for 1997-2000.
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Conclusion: Early TRM improved according to the accumula-
tion of experiense and overall early TRM was 9.0% . Especially
about CML, no significant difference between R-BMT and U-
BMT was seen with respect to early TRM and 5-year DFS.
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TANDEM ALLOGENEIC STEM CELL TRANSPLANTATION (ALLOSCT)
FOR PATIENTS WITH LEUKEMIA WHO RELAPSED FOLLOWING NON-
MYELOABLATIVE STEM CELL TRANSPLANTATION (NST)
Nagler, A.; Or, R.; Varadi, G.; Shapira, M.; Slavin, S. Hadassah Uni-
versity Hospital, Jerusalem, Israel
Relapse is the major cause of therapy failure in leukemia pts.
following alloSCT. Second alloSCT is a therapeutic option for
leukemia pts. who relapse post-alloSCT, however, transplant
related toxicity tend to be high and there is an increased risk of
graft rejection or non-engraftment if the same donor is used. We
present our experience with 9 pts, 7 male and 2 female, aged a
median 32 (20-51) years, 4 of whom had ALL, 4 AML, and one
CML (AP), who relapsed after alloSCT, and underwent a second
NST from the same HLA matched sibling donors. All received
non-myeloablative conditioning (Flu/Bu/ATG-7, TBI/Flu-2,) for
their ﬁrst alloSCT. Six pts. achieved full donor chimerism, while
3 were chimera. Relapse occurred 6 (3-21) months following
their transplant. Conditioning for the second alloSCT consisted
of non-myeloablative (n-7) or myeloablative (n-2) regimens. All
the pts. received G-CSF mobilized unmanipulated grafts,
13.1(4.9-19.7)x108MNC/kg and 10.1(3.5-22.9)x106 CD34+/kg.
Seven pts. (78%) engrafted with full donor chimerism, achieving
WBC>1x109/L at day +22(15-27), ANC>0.5x109/L at day +21.5
(15-27) and plts>25x109/L at day +18(12-33). Two pts. failed to
engraft and died of resistant disease 7 and 17 months post-second
alloSCT. One pt. relapsed and died 4 months post-transplant.
Two pts. developed grade IV acute graft versus host disease
(GVHD) and aspergillosis, and died 3 and 4 months post-second
alloSCT. Four pts. are alive, 3 of them with mild/moderate
extensive chronic GVHD, after a median follow-up of 30 (15-55)
months. In conclusion, tandem alloSCT from the same HLA
matched donor for pts. with relapsed leukemia following NST is
feasible. Most of our pts. (78%) engrafted with full donor
chimerism. Although a second alloSCT, even after non-myeloab-
lative conditioning, carries a considerable risk of death due to
recurrence of basic disease or GVHD, it may be a therapeutic
option for salvaging extremely poor risk pts.
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LEPROSY AND BONE MARROW TRANSPLANTATION—THREE DIFFER-
ENT PRESENTATIONS
Paton, E.A.1; Stracieri, A.B.1; Coutinho, M.A.1; Simões, B.P.1; Castro,
N.2; Barros, J.C.2; Vigorito, A.3; Trabasso, P.3; Souza, C.A.3; Voltarelli,
J.C.1 1. HCFMRP - USP, Ribeirao Preto, Brazil; 2. ISCMSP, Sao
Paulo, Brazil; 3. UNICAMP, Campinas, Brazil
Case 1: A 39 y.o. CML patient with disseminated erythematous
skin lesions histologically compatible with lepromatous leprosy
submitted to an alloidentical BMT. He was treated with Oﬂoxacin
for 30 days with complete regression of skin lesions. On day 110
the patient presented a leprosy reverse reaction responsive to cor-
ticotherapy. Currently he is on day 1020 in molecular remission
for CML, with mild skin lesions under specific treatment and
tapering corticosteroid dose. Case 2: A 17 y.o. CML patient sub-
mitted to an alloidentical BMT who developed lepromatous lep-
rosy on day 223, treated with Rifampicin, Clofazimine and Dap-
sone. Skin lesions improved after 30 days and the patient is under
maintenance antileprosy treatment. Case 3: A 36 y.o. CML
patient with a previous lepromatous leprosy diagnosed 20 years
before admission for an allogeneic PBSC transplantation with no
active leprosy at this time. On day 318 she evolved with extensive
chronic GVHD and sharp pain and paresthesia in upper and lower
limbs treated with CsA + prednisone. A nerve biopsy evidenced a
chronic neuritis with demyelinating process and inflammatory
activity related to the patient’s previous leprosy with negative
baciloscopy and suggestive of an immune complex disease. She
had a partial response of GVHD and neurological symptoms after
an alternate protocol treatment with CsA + PDN and a complete
response to MMF + Prednisone. Currently she is on day 707 with
stable symptomatology. There are no reports in the literature on
the association of leprosy with HCT. This association may be due
to immunossupression causing oportunistic mycobacterium infec-
tion as shown in cases 1 and 2 or to immune mediated reaction
exarcebated by GVHD as shown in case 3. Leprosy must be con-
sidered in the differential diagnosis of skin and neurological
lesions after HCT.
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THE UTILITY OF A PROGNOSTIC SCORING SYTEM FOR ALLOGENEIC
STEM CELL TRANSPLANTATION IN PATIENTS WITH CHRONIC
MYELOID LEUKEMIA
Qazilbash, M.H.; Lynch, J.P.; Beall, C.L.; Auber, M.; Weisenborn, R.;
Bunner, P.; Ericson, S.G. West Virginia University, Morgantown, WV
Background: Allogeneic stem cell transplantation from a related
or unrelated donor is the treatment of choice for selected patients
with chronic myelogenous leukemia (CML). However, it is associ-
ated with a high risk of treatment-related morbidity and mortality.
There are several other available therapies with encouraging
short-term beneﬁts. For appropriate decision making about trans-
plant, a simple scoring system to assess the risk is needed. We ana-
lyzed the utility of a scoring system, ﬁrst reported by Gratwohl et
al, from the European Group for Blood and Marrow Transplanta-
tion (EBMT).
Methods: We analyzed the data from 30 patients who under-
went allogeneic transplantation at our institution between 1994
and 2000, using the EBMT scoring system. The scoring system
was based on previously reported major pretransplant risk factors:
donor type; stage of disease at the time of transplantation; age of
recipient; sex of donor and recipient; and interval between diagno-
sis and transplant. We analyzed the probabilities of overall survival
(OS), leukemia-free survival (LFS) and transplant-related mortality
(TRM) with respect to these risk factors. The lowest possible score
was 0 and the highest possible score was 7.
Results: Seventeen patients had a score of 0-2 and 13 patients
had a score of 3-7. Using Kaplan-Meier analysis, the estimated 4-
year LFS and OS for patients with a score of 0-2 were 48% and
55%, respectively. In contrast, the estimated 4-year LFS and OS
for patients with a score of 3-7 were 10% and 10%, respectively.
The TRM was 35% in patients with a prognostic score of 0-2, and
61% in patients with a score of 3-7.
Conclusion: This simple scoring system based on ﬁve prognostic
factors appears to give satisfactory risk assessment for patients
undergoing allogeneic transplantation for chronic myeloid
leukemia. It may play an important role in choosing the appropri-
ate therapy for patients with CML.
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ALLOGENEIC STEM CELL TRANSPLANTATION WITH NON-MYELOAB-
LATIVE CONDITIONING IS ASSOCIATED WITH REDUCED LEVELS OF
TUMOR NECROSIS FACTOR-α COMPARED TO MYELOABLATIVE
CONDITIONING
Reddy, V.; Salansky, J.; Devidas, M.; Bohsali, K.; Lincoln, G.; Pollock,
B.; Boyette, R.; Wingard, J.R. University of Florida, Gainesville, FL
Allogeneic stem cell transplantation (SCT) with non-myeloabla-
tive conditioning is promising due to the potential for reduced
toxicity compared to myeloablative conditioning. We investigated
the hypothesis that non-myeloablative conditioning decreases
plasma levels of tumor necrosis factor-α (TNF), compared to an
increase with myeloablative regimens. We performed a cohort
analysis on 32 consecutive patients undergoing SCT during the
period of July 1999 to September 2000. Nineteen patients
received SCT with myeloablative conditioning and 13 patients
received non-myeloablative conditioning with a fludarabine,
busulfan and ATGAM or a ﬂudarabine and TBI (200cGy) based
regimen. Blood samples were collected as baseline prior to condi-
tioning (pre-chemo), on day 0 prior to stem cell infusion and day
+7 after transplant. Plasma TNF was measured by ELISA. We
assessed the differences in the TNF levels between each time
point and termed as Diff 1 (day 0-pre-chemo) Diff 2 (day +7-day
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0) and Diff 3 (day +7 −pre-chemo) if the medians of each of the
differences were significantly different from zero. The median
TNF levels for the myeloablative group was 22 pg/ml (pre-
chemo) and increased to 31 pg/ml (day 0) and 110 pg/ml (day +7)
(Diff 3, p=0.018). On the contrary, the non-myeloablative group
had a baseline TNF of 119 pg/ml (pre-chemo) that dropped to 14
pg/ml at day 0 (Diff 1, p=0.003) and 19pg/ml at day +7. When
comparing the two groups (Wilcoxon rank sum test), the change
in TNF levels was signiﬁcantly different from pre-chemo to day 0
(diff 1, p=0.011) and day +7 (diff 3, p=0.006). Our results demon-
strate that non-myeloablative conditioning is associated with a
reduction in TNF levels compared to a significant increase in
TNF levels with myeloablative regimens. Therefore, non-mye-
loablative conditioning regimens may be less toxic and better tol-
erated due to reduced levels of TNF in the post-transplant period
compared to myeloablative regimens.
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SECOND ALLOGENEIC TRANSPLANT FOR LEUKAEMIA AFTER FAILED
FIRST AUTOLOGOUS TRANSPLANT
Rowlings, P.A.; Greenstein, V.; Nivison-Smith, I.; Dodds, A.; Brad-
stock, K.; Szer, J. Australasian Bone and Marrow Transplant Recipient
Registry, Sydney, Australia
We evaluated the outcome of second allogeneic haematopoietic
stem cell transplantation in 42 patients with leukaemia who had
relapsed following an initial autologous transplant. Thirty-four
patients had AML, 4 had ALL and 4 had CML. The median age
of patients was 21 yrs (2-55yr) and median time between trans-
plants was 11 mos (2.6-52 mos). 23 patients were in 2nd complete
remission (CR), 12 in first relapse, 2 in 3rd CR and 5 in 2nd
relapse. Allogeneic donors included HLA identical relatives
(n=16), matched unrelated donors (n=18), mismatched relatives
(n=6) and mismatched unrelated donors (n=2). For the 42 patients
in the group overall, the 3 yr probability of survival was 27 (12-
42)%. The 4 patients with ALL all relapsed and died at a median
of 2 mos post-transplant. Of the 4 CML patients, 1 was alive at 26
mos post-transplant the others died at 1, 7 and 12 mos. For the 34
AML patients, 100 day and 3 year probabilities of survival were
62(45-79)% (95% CI) and 31(13-49)% respectively. Of the 21
AML patients who died post-transplant, 10 relapsed at a median
of 10.5 mos (0.5-38mos). Comparing HLA-identical sibling
(n=16) vs unrelated and mismatch related donors (n=26) the 3 year
probability of survivals were 27(2-52)% vs 28(12-46)% (p=0.17).
Male patients had a three year probability of survival of 37(16-
58)% compared to female patients 22(1-43)%, (p=0.58). Patients
aged < 15yrs (n=13), 16-30 yrs (n=15) and >31 yrs (n=14) at trans-
plant had probabilities of survival of 36(4-68)%, 31(7-55)% and
14 (0-32)%, respectively (overall p= 0.008). Probabilities of sur-
vival for patients with interval between transplants of <1yr (n=23)
were 21(3-39)% vs 31(5-56)% (p=0.21) for those with an interval
greater than 1 year.
In conclusion second allogeneic after failed autologous trans-
plant for leukaemia is a reasonable salvage therapy particularly in
younger patients.
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DURABLE ENGRAFTMENT AFTER NON-MYELOABLATIVE TRANSPLAN-
TATION: AN ISSUE?
Schouten, H.C.; Jansen, M.; Lalisang, R.; Bos, G.; Jansen, R.;
Wagstaff, J. University Hospital Maastricht, Maastricht, Netherlands
Because of its reduced morbidity and mortality compared to
standard allografting, non myeloablative transplants have gained
an increasing popularity. However, long term engraftment and
efﬁcacy data are scarce. To obtain toxicity, engraftment and efﬁca-
cy data we started a phase I/II study in patients with metastatic
breast cancer (n=5) or hematologic malignancies being non-stan-
dard allografting indications (n=6) using a cyclophosphamide (60
mg/kg x1) fludarabine (25 mg/m2x3) conditioning regimen fol-
lowed by stem cell transplantation using an HLA identical sibling
donor. Graft vs. host prophylaxis consisted of standard
cyclosporine/methotrexate. Cyclosporine A was tapered after day
30. After 6 pts adjuvant DLI infusions (107 T cells/kg) were
included in the protocol at day 30 and ﬂudarabine was increased
from 3 to 5 days. Chimerism data were obtained at days 30, 60, 90
and 300. Donor engrafment was deﬁned as more than 75% donor
cells using either sex chromosomes or informative VNTRs as
marker. Up to now 11 pts have been included. Median follow up is
276 days. No severe toxicity (>WHO 2) was seen. Treatment
related mortality (at day 90) is 0%. At day 30 5/11 had donor
engraftment; at day 60 4/11; at day 90 4/7; at day 300 1/2 evalu-
able patients. However, 7/11 pts either did not engraft or rejected
after engraftment their graft. There is, up to now, no clear rela-
tionship between engraftment and transplant size or ﬂudarabine
dose and the adjuvant administration of DLI at day 30. In one pt
an anti-tumor effect was observed. Graft vs. host disease was seen
in 2 pts (one acute and one chronic GvHD), which was fatal in one
pt. We conclude that non-myeloabltive transplantation has a low
morbidity and mortality but that engraftment after our condition-
ing has to be improved. Therefore, the concept of non-myeloabla-
tive transplants needs further development and clinical trials.
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ENGRAFTMENT OF T CELL DEPLETED MARROW ALLOGRAFTS: A SIN-
GLE CENTER EXPERIENCE
Magalhaes-Silverman, M.; Lee, C.; Hohl, R.; Gingrich, R.; Ritchie, J.
University of Iowa, Iowa City, IA
The backward stepwise model building technique was used to
identify factors associated with time to neutrophil and platelet
engraftment in 182 patients who underwent T cell depleted allo-
geneic bone marrow transplantation. Variable under study includ-
ed: mononuclear cell dose infused, T cell dose infused, type of
transplant (related vs unrelated), HLA match (match vs mis-
match), diagnosis, age and donor/recipient sex-match. T cells
were depleted by an anti-CD3 IgG2 monoclonal antibody
(muromonab-CD3,Ortho Biotec, Raritan, NJ). T cell content of
the graft was titrated according to GVHD recipient risk (Biology
of Blood and Marrow Transplant. 5: 15-27, 1999). The median
age of patients (pts) was 43 years ( range 18-62). Diagnosis: ALL
(12 pts), AML/MDS (53 pts), CML (45 pts),NHL (36 pts), MM
(16 pts) SAA (8pts), other (12 pts).Median number of mononu-
clear cells in the graft was 1.8x108/Kg and the median number of
T cells was 0.8x105/Kg. The median time to ANC ≥0.5x109/L was
15 days and to a platelet≥20x109/L was 46 days. All but 11 pts
(6%) achieved neutrophil engraftment. Platlet engraftment was
sustained in 116 pts (64%). Variables favorably associated with
neutrophil engraftment were mononuclear cell dose ( p=0.003,
RR=1.48) and degree of HLA match (p=0.005, RR=1.86). T cell
dose did not impact on neutrophil engraftment (p=0.305).
Mononuclear cell dose also inﬂuenced favorably platelet engraft-
ment (p=0.001, RR=1.73). Pts with CML (RR=1.59) and MM
(RR=1.41) were for likely to have platelet engraftment then pts
with other diagnosis. Other variables favorably associated with
platelet engraftment include: related donor (p=0.001, RR=2.99),
donor-recipient of same sex (p=0.025, RR=1.57).
Our data show that satisfactory neutrophil engraftment can be
achieved in pts transplanted with marrow allografts treated with
anti CD3 monoclonal antibody. T cell content of the graft does
not seem to have an impact on engraftment.
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CHEMOTHERAPY FOLLOWED BY DONOR LYMPHOCYTE INFUSIONS
FOR TREATMENT OF ACUTE LEUKEMIA RECURRENCE AFTER ALLO-
GENEIC STEM CELL TRANSPLANTATION (ALLO-SCT)
Taylor, K.; Finiewicz, K.J.; Moreb, J.S.; Reddy, V.; Khan, S.A.;
Boyette, R.; Shroff, S.; Roque, D.; Manion, K.; Wingard, J.R. Univer-
sity of Florida, Gainesville, FL
DLI is not as effective in the treatment of relapsed acute
leukemia (AL) post-BMT as in the treatment of chronic
leukemia, possibly secondary to both the aggressive nature of AL
and less pronounced graft versus leukemia effect (GVL). Control-
ling tumor burden with chemotherapy prior to DLI could allow
sufﬁcient time for GVL effect and thus improve effectiveness of
DLI in AL.
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We retrospectively reviewed 17 cases of chemotherapy prior to
DLI for recurrent AL after ASCT. Underlying diseases at the
time of DLI included: AML (n = 5); secondary AML arising from
MDS (n=5); ALL (n = 3); and CML in blast crisis (n = 2). The
median time to recurrence after ASCT was 6 mo (range 0-23).
The chemotherapy regimens included: FLAG (9), Ida/Ara-C (3),
Ida/Ara-C/VP16 (1), FLANG (2), VCR/Pred/MTX/Ifos/Ara-C
(3), and CECA (1). Fifteen cases were evaluated for response 2-4
weeks after DLI. Leukemia cell clearance occurred in 11 cases; 4
cases did not respond and 2 cases were unevaluable due to death
prior to disease evaluation. Hematologic recovery (ANC>500,
plt>20,000) occurred in all evaluable cases following treatment.
Relapse occurred in 8 cases at a median of 5 months (range 2-13).
Five patients had durable responses lasting a median of 13.7
months (range 6-29+). Three patients are alive in remission with a
mean survival of 20.7 months (range 12-29). Only those patients
who developed cGVHD had durable responses.
Chemotherapy prior to DLI in ASCT patients is feasible and
does not appear to affect graft function. A larger study comparing
chemotherapy followed by DLI to DLI alone is warranted to con-
ﬁrm these results.
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THE SAFETY OF AMPHOTERICIN B LIPID COMPLEX IN BMT
PATIENTS
Wingard, J.R.1; Matera, J.A.2 1. Shands Hospital, Gainesville, FL; 2.
The Liposome Company, Princeton, NJ
Background: Amphotericin B is the mainstay of antifungal ther-
apy but clinical utility is limited by associated toxicities, predomi-
nantly nephrotoxicity. Abelcet (ABLC) was developed to preserve
activity while avoiding nephrotoxicity.
Methods: A multicenter database (CLEAR) was queried to iden-
tify patients with BMT who received ABLC from 1996 through
1999. Variables included diagnostic site, treatment dosing and
duration, clinical and mycological response, and serum creatinine
values (SCr).
Results: Of 2,844 patients, 669 had BMT as an underlying con-
dition. ABLC was given to 74/570 allo-BMT patients as ﬁrst-line
therapy and 496/570 as second-line, while 22/99 auto-BMT
patients received ﬁrst-line ABLC and 77/99 received second-line.
The median dose was comparable for all groups (4.0 - 4.5
mg/kg/day); duration was longer in the allo-BMT group (1st and
2nd line respectively; allo 27 and 16 days vs. auto: 9 and 11 days).
First-line allo-BMT patients had a 0.2mg/dL median change in
SCr. SCr doubled in 16 patients but remained ≤2.5mg/dL in 69%
(11/16)of the patients. In the second-line allo-BMT population
median change in SCr was 0.3 mg/dL with a 18% (86/482) dou-
bling and 43% (37/86) were ≤2.5 mg/dL. First-line auto BMT
patients had a 0.1mg/dL median change in SCr with 18%
(3/17)doubling and all patients remained at <2.0 mg/dL and the
second-line allo-BMT patients showed no median change in SCr
with an overall 12%(9/73) doubling and 45% (6/9) remained at
<2.5 mg/dL. The SCr was >2.5 mg/dL in 9% (57/642) of the
entire population. Clinical outcome (cured and improved) for
evaluable patients was 30% (113/374) for allo’s and 48% (30/63)
for auto’s. An additional 23.3% had a stable response.
Conclusion: Analysis of these data show that ABLC is safe and
effective within this patient group.
25
A RETROSPECTIVE ANALYSIS OF RED BLOOD CELL (RBC) TRANSFU-
SION REQUIREMENTS DURING ALLOGENEIC BONE MARROW TRANS-
PLANTATION (alloBMT)
Yee, A.1; Xenocostas, A.1; Wong, C.J.2; Sutton, D.M.1; Lipton, J.H.1;
Kiss, T.L.1; Messner, H.A.1 1. The Princess Margaret Hospital/Univer-
sity Health Network and the University of Toronto, Toronto, ON,
Canada; 2. London Clinical Trials Research Group, Robarts Research
Institute, London, ON, Canada
Most recipients of alloBMT require homologous transfusions of
RBC. We undertook a retrospective study to evaluate the utiliza-
tion and the risk factors for RBC transfusions such as age, diagno-
sis, degree of HLA match, disease status at BMT, graft-versus-
host disease (GVHD) and ABO blood group compatibility. 519
patients consecutively transplanted at the Princess Margaret Hos-
pital between January 1995 and March 2000 were studied. The
number of RBC transfusions was determined for the following
periods: 0-2, 2-4 and 4-6 months after BMT.
The transfusion requirements were greatest during the early
period and declined with time. The mean number of units trans-
fused/patient ± SD from 0-2 mo = 6.7±6.4U, 2-4 mo = 3.1±5.5U
and 4-6 mo = 2.0±4.7U. The total number of units transfused to
this cohort of patients was 5395 where 3489U were utilized in
the ﬁrst 2 months. 11% of our patients did not require a RBC
transfusion.
An increased transfusion requirement was associated with lower
pre-conditioning hemoglobin (pre-CON Hb) levels, ABO incom-
patibility between donor and recipient, BMT in patients trans-
planted with more advanced disease, the use of unrelated donors
and older age. The presence or absence of GVHD did not inﬂu-
ence the transfusion requirements. The association with pre-
CON Hb levels, which were determined 10-15 days prior to
BMT, remained signiﬁcant when adjusted for the other risk fac-
tors (p<0.001). The mean number of units transfused/patient ± SD
over the 6 mo follow-up period was 13.3±12.5U, 12.6±12.1U,
10.9±10.5U, 9.0±12.6U and 6.5±8.7U for patients with pre-CON
Hb ≤100g/L, 101-110g/L, 111-120g/L, 121-130g/L and >130g/L,
respectively.
In summary, we have identified the pre-CON Hb level as an
independent risk factor for RBC transfusions post alloBMT. Ran-
domized controlled trials should be performed to evaluate the efﬁ-
cacy of increasing pre-CON Hb levels, by interventions such as
recombinant erythropoietin therapy, in reducing transfusion
requirements.
(Acknowledgements: This work has been supported by
Janssen-Ortho.)
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PROTECTION OF NORMAL TISSUE BY AMIFOSTINE (ETHYOL) FROM
THE CYTOTOXIC EFFECTS OF MEGATHERAPY WITH AUTOLOGOUS
STEM CELL RESCUE IN CHILDREN
Kavan, P.1,2; Stankova, J.2; Smelhaus, V.2; Kabickova, E.2; Eckshlager,
T.2; McClain, K.L.3; Gajdos, P.2 1. Div. Ped. Hematol/Oncolog.,
MCH, MUHC, Montreal, PQ, Canada; 2. Faculty Hospital Motol,
Prague, Czech Republic; 3. Texas Children′s Cancer Center, Baylor
College of Medicine, Houston, TX
Background: Amifostine is currently being investigated as a pro-
tector of normal tissues during chemotherapy and/or radiotherapy.
In children undergoing megatherapy with autologous hemato-
poeitic stem cell rescue (AHSCR) organ toxicities are dose limit-
ing. Aim of study: Can megatherapy-related toxicity in children be
reduced by amifostine? Patients and methods: Seventy amifostin
administered pts were compared to the historical seventy pts group
without amifostine. Diagnoses included: Ewing′s sarcoma, soft tis-
sue sarcoma, NHL, neuroblastoma, germ cell tumor, Hodgkin
disease. Patients with abnormal parameters of organ function prior
to AHSCT were excluded. Myeloablative conditioning regimens
included platin derivates, alkylating agents +/- TBI. As concerns
typ of the graft, PBPC, BM or combination of both were used so
that the required minimal count of CD 34+ 1.5x106 /kg of body
weight and CFU GM 30x104/kg of body weight were achieved.
Study patients received amifostine (Ethyol, Schering Plough) 750
mg/m2 15 min. prior to and again every 8 h after initiating the
infusion if cytostatics administered continuously.
Results: During the amifostine administration patients required
intensive calcium replacement (2-6 mmol/kg/day). Increased fre-
quency of emesis was directly related to administration of amifos-
tine. The following of grade 3/4 toxicity comparisons (CCG
guidelines) differ signiﬁcantly in favour of the amifostine+ group:
mucositis: 12 vs 24 pts, liver toxicity: 9 vs 21 pts. There were
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found significant shortage of hematopoietic recovery, decreased
number of packed platelet transfusions units and erythrocyte
transfusions units. The number of hospitalization days (25 vs 29)
and the number of days with ATB (13 vs 16) was in favour of ami-
fostine+ group. Neutropenia (ANC < 0.1x109/L) occured D+4 in
the amifostine group and D+1 in the controls. Results did not dif-
fer signiﬁcantly in terms of lung and renal toxicity. Conclusion:
Amifostine protected patients from mucositis and decreased the
days of hospitalization, with fever, antibiotics administration and
amount of erythrocyte support.
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THE VALUE OF EX VIVO DEFEROXAMINE PURGING OF AUTOLOGOUS
GRAFTS IN CHILDREN WITH HIGH RISK NEUROBLASTOMA
Kavan, P.1,2; Stankova, J.2; Smelhaus, V.2; Kobylka, P.2; Eckshlager,
T.2; Gajdos, P.2; Skala, J.P.3 1. Div. Ped. Hematol/Oncolog., MCH,
MUHC,Montreal, Ca, Montreal, PQ, Canada; 2. Faculty Hospital
Motol, Prague, Czech Republic; 3. Dept. of Ped. Oncol. Univ. Of British
Columbia, Vancouver, BC, Canada
Aim of study: The goal of Czech Pediatric Oncology Group was
to determine if the frequency and sites of neuroblastoma (nbl)
relapses after autologous stem cell transplantation differ in the
groups receiving deferoxamine (DFO) ex vivo purged or unpurged
graft and clarify the role of purging. Patients and methods: From
Jan. 1992 to Dec. 1998 40 pts with HR neuroblastoma in the ﬁrst
remission underwent AHSCT: 28 pts with DFO purged grafts
and 12 pts with unpurged grafts. The treatment schedule consist-
ed from induction chemotherapy (CCG 3891), surgery ± local
radiation followed by myeloablative regime (MEC). The grafts
were harvested after 3-5 cycles of chemotherapy and ex-vivo
purged for 72 hrs with 50µm iron chelating agent deferoxamine.
With respect to decrease in the CFU-GEMM and CD 34+ cells
after purging, the harvest procedure was repeated in 28 patients.
Hypocellularity of the graft was the reason for contra-indication
of high dose therapy in one patient. Residual NBL cells were
assessed by FISH and PCR technique. 18 pts (64%) transplanted
with DFO purged grafts died by diseases progression, 9 (32%)
remain PFS with a median follow-up 41 mos. There was one
TRD. The most common site of relapses were primary tumor bed
and bones (n=16). There was one CNS relapse and one recurrent
lung disease. In group with unpurged graft 2/12 pts (17%) remain
in continuous remission with a median follow-up 52 mos. Tumor
recurred in sites of initial involvement in all of them. Conclusion:
There was slightly better trend of PFS in favour of purged group
(32 % vs 12%). Despite laboratory proven efficacy of ex vivo
purging, we did not ﬁnd any statistically signiﬁcant clinical beneﬁt
of ex-vivo purging. The relapses occured in both groups in origi-
nal sites of disease. Statistically important were local radiotherapy
and maintenance therapy.
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FACTORS INFLUENCING HAEMATOLOGICAL RECOVERY AFTER
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION (PBSCT)
Komurcu, S.; Yilmaz, I.; Ozturk, B.; Arpaci, F.; Ozet, A.; Hayran,
M.; Sengul, A.; Yalcin, A. Gulhane Medical Military Academy,
Ankara, Turkey
High dose chemotherapy and autologous peripheral blood stem
cell support provides durable complete responses in several solid
tumors and lymphomas. The major morbidity and mortality result
from infectious and bleeding complications during 2-4 week apla-
sia until the haemotopietic recovery. So time to achieve leucocyte
and platelet engraftment is important. We examined 137 patients
(78 men, 50 women) undergone PBSCT to determine the factors
that might be involved in successful engraftment following admin-
istration of autologous peripheral blood stem cell after myeloabla-
tion. Patients were histologically confirmed as breast cancer
(n=46), non-Hodgkin’s lymphoma (n=25), Hodgkin’s lymphoma
(n=22), osteosarcoma (n=15), germ cell tumor (n=8) and others
(n=21). The median time to achieve 1000/mm3 leucocyte and
50,000/mm3 platelet were 11 (range 7-40) and 16 (range 3-60)
days, respectively. Factors investigated in an attempt to determine
their effects on marrow engraftment were: Gender, diagnosis,
radiotherapy exposure in pretransplantation period, type of
growth factor used (G-CSF or GM-CSF) after infusion, the total
number of total nuclear cells and CD 34(+) cells infused, total
product volume pheresed, the number of days with fever in early
post-transplant period. Our data showed that platelet engraftment
was earlier in women (p=0.0002). The platelet engraftment peri-
ods in Hodgkin disease and non-Hodgkin′s lymphoma were
longer than the other diagnoses. Both leucocyte and platelet
engraftments delayed due to prior exposure to radiotherapy
(p=0.003 and p=0.0001, respectively). The harvest volume and the
number of days with fever were correlated positively with platelet
recovery (r=0.428, and r=0.442 respectively).
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A PROSPECTIVE SINGLE CENTER EXPERIENCE OF AUTOLOGOUS
PBSCT FOR ADULTS WITH ALL: THE ROLE OF TBI, HIGH-DOSE
CYTOSINE ARABINOSIDE AND MELPHALAN (TAM) AS A PREPARA-
TIVE REGIMEN
Lee, S.; Kim, D.; Min, C.; Lee, J.; Min, W.; Kim, C. Catholic Hemo-
poietic Stem Cell Transplantation Center, The Catholic University of
Korea, Seoul, South Korea
Because leukemia relapse is still the most common cause of
treatment failure after transplantation, considerable interest
remains for the evaluation of new approaches aimed at improving
the antileukemia efﬁcacy and the probability of survival. There-
fore, we prospectively evaluated the efﬁcacy of this conditioning
regimen in adults with ALL who underwent autologous PBSCT.
Twenty-six consecutive patients with successful phenotype and
karyotype were enrolled onto the study. There were 20 males and
6 females with median age 22 (range, 15-41) years. The distribu-
tion of FAB and immunophenotypes was as follows: L1 (n=15), L2
(n=11), precursor B (n=22), T (n=4). The adverse karyotype was
present in 7 (26.9%) cases [Ph+ (n=5), 11q23 (n=2)], whereas the
normal karyotype was demonstrated in 15 (57.7%). Seventeen
patients (65.4%) were categorized as high-risk ALL [patients with
any of the following features: age >30 years, adverse karyotypes
(Ph+, 11q23), required >1 induction course, WBC >30,000/µL or
CR2 at the time of transplantation]. The conditioning regimen
consisted of TBI (12 Gy), ara-C (2 g/m2 every 12 h for six doses)
and melphalan (120 mg/m2). All assessable patients were engrafted,
with a median time of 11 and 23 days for neutrophil and platelet
recovery, respectively. The preparative regimen was well tolerated
and no patient died as a result of regimen-related causes. After
hematologic recovery, oral maintenance chemotherapy was
administered for 2 years. Nine (34.6%) patients relapsed at a
median time of 12 months (range, 3-35 months) after transplanta-
tion. With a median follow-up of 27 months, the estimated proba-
bility of DFS was 69±9% and 55±11% at 2 and 5 years, respective-
ly. With this regimen, there was a significant difference in the
probability of DFS between standard and high-risk patients
(75±21% vs 41±14%, p=0.04). In conclusion, this preparative regi-
men for adult with ALL was feasible and safe in an autologous
transplant setting.
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ISOLATION OF HUMAN BLOOD DENDRITIC CELLS FOR CLINICAL
APPLICATIONS
Lopez, J.A.; Bioley, G.; Ho, C.S.; Vuckovic, S.; Gilleese, M.; Munster,
D.; Hart, D.N. Mater Medical Research Institute, South Brisbane,
Australia
Dendritic cells (DC) are unique in their capacity to present
antigen to naïve lymphocytes and, therefore, ideal candidates
for vaccine delivery. Circulating DC may have various advan-
tages over currently used in vitro derived Mo-DC for this pur-
pose. Blood DC preparations: 1) are in a defined state of differ-
entiation, 2) have the ability to respond to physiological stimuli
(e.g. for migration) and the capacity to take up and process anti-
gen, 3) are likely to be homogeneous and importantly, 4) will
not be exposed to the effect of exogenously added cytokines.
Comparative studies suggest blood DC have increased efficien-
cy for presenting tetanus toxoid antigen, when compared with
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Mo-DC. We describe the isolation of human blood DC isola-
tion based on the CMRF-44 and CMRF-56 antibodies that
identify DC activation antigens. After overnight culture of
PBMC, biotinylated CMRF-44 was used in a single purification
step with streptavidin magnetic beads; this approach yielded up
to 75% CMRF-44+ cells including up to 50% CMRF-
44+CD14-CD19- DC compared to 0.5% starting DC popula-
tion. In repeated experiments (n=22), the mean yield of CMRF-
44+ cells was variable depending on individuals with an average
53% (range 32%-65%); CMRF-44- cells included CD3+,
CD19+, CD14+ and CD16+ cells at variable percentages. This
procedure yielded, on average, 0.76% PBMC (range 0.32%-
1.08%). Similar results were obtained using biotinylated
CMRF-56 antibody. A new generation magnetic beads coupled
to biotin-specific antibody generated a better purity of CMRF-
44 cells (up to 84%) with an average of 62% (range 48-84%),
from which 33% (range 24-41%) were DC. The capacity of
CMRF-44+ fraction obtained after the one step magnetic sepa-
ration to elicit an allogeneic MLR was increased in comparison
to whole cultured PBMC. No allostimulatory activity was
found in the CMRF-44- fraction. We are currently studying
the viability of CMRF-44+ DC after purification and their acti-
vation status after the procedure.
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INTENSIFICATION/ENHANCEMENT TREATMENT WITH ATMO IN LYM-
PHOMAS—INDICATIONS AND PROGNOSTIC FACTORS; EXPERIENCE
IN ONE CENTRE: THE MACIEL HOSPITAL, MONTEVIDEO, URUGUAY
Magariños, A.; Gabus, R.; Zamora, M.; DeLisa, E.; Landoni, A.I.;
Uturbey, F.; Canessa, C.; Bodega, E. Hospital Maciel., Montevideo,
Uruguay
Introduction.High doses chemotherapy followed by stem cells
infusion has been used since the beginning of the 80s in agres-
sive non-Hodgkin lymphomas (NHL) during relapse with a con-
siderable improvement of the outcomes up-to-date conventional
rescue chemotherapy. It is currently the formal indication in
relapses of agrresive NHLs. Different groups have supported
this type of procedure as consolidation therapy after 1st.CR in
patients with poor prognosis of cure(intermediate and highrisk
IPI). In Hodgkin Lymphomas (HL) the outcomes have been sat-
isfactory in primary refractory and relapses and the idea is to
identify high risk patients in whom the more aggressive front
line conducts may help to avoid the passage to the refractory
phase. We show the experience obtained with ATMO in Lym-
phomas at our Centre.
Materials and Methods: 37 patients (March’95-March’00). 24p.
with NHL: 47% high risk IPI, 33% intermediate-high and 20%
low risk. According to the REAL classiﬁcation: 19p. with aggres-
sive histological forms, 3 very aggressive and 2 indolent. Situation
previous ATMO: 12 in 1st.CR, 7 in 2nd.CR, 4 in PR, 1 in
Relapse. 13 patients with HL: Histological form: 9 NE, 3 MC, 1
noteval. Situation previous ATMO: 3 in 1st.CR, 4 in 2nd.CR, 4 in
PR, 2 in Relapse.
Results: Overall survival(OS) for NHL: 55% for 35.8
months(28.0-43.5). OS for HL:62% for 51.8 months. OS for
aggressive NHL:58% for 38 months. The NHL transplanted in
1st.CR. presented an OS of 74% at 18 months. In 2ndCR 55% at
33 months. High risk IPI OS:55% for 18 months(9.9-26.2). Dis-
ease free survival(DFS) for NHLwas 58% at 22 months and 59%
for HL at 17 months.
Discussion: Intensification with ATMO provides encouraging
results in aggressive and high risk IPI NHLs including those in
1st.CR. The formal indication for HL correspond to the relapse
period. This group highlights the good course of patients in
1st.CR with severe pulmonary extranodal participation (one with
large pulmonary tumoral masses and another with chestpleural
and pericardic involvement with cardiac tamponade) which could
be identiﬁed as poor prognostic patients.
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INCIDENCE AND FACTORS ASSOCIATED WITH THE ENGRAFTMENT
SYNDROME IN AUTOLOGOUS STEM CELL TRANSLANTATION
Maiolino, A.; Nucci, M.; Ferreira, J.; Portugal, A.; Bisoli, I.; Pulcheri,
W. Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Engraftment syndrome (ES) is an increasingly reported compli-
cation of autologous bone marrow transplant (ABMT). In order to
assess its incidence and to identify possible risk factors, we retro-
spectively analyzed 52 patients who were submitted to ABMT. ES
was deﬁned as the occurrence of a new fever and a skin rash mim-
icking acute graft versus host disease, occurring within 24 h of the
appearance of neutrophils in the peripheral blood. We compared
patients with ES to those without ES regarding baseline clinical
characteristics, previous treatment, number of CD34+ cells
infused, time of G-CSF administration, documentation of infec-
tion, duration of neutropenia, antibiotic use and the outcome. The
male:female ratio was 21:31, and the median age was 44.5 (range
17-65). Underlying diseases were: multiple myeloma (42%) non-
Hodgkin′s lymphoma (23%), Hodgkin′s disease (19%), breast
cancer (10%) and acute myeloid leukemia (6%). The incidence of
ES was 15.4% (8 cases). Other manifestations included hypoalbu-
minemia (86%), weight gain (62%), diarrhea (50%) and pul-
monary infiltrates (50%). Steroids were used in 6/8 cases with
marked improvement in 5. One patient died. ES occurred more
frequently in females (7/8 vs. 24/44, p=0.12, 95% CI 0.06 - 0.60),
and did not occur when the source of stem cells was the bone mar-
row. Patients with ES had a more prolonged duration of hospital-
ization (p=0.09) and received amphotericin B more frequently (6/8
vs. 10/44, p=0.007, 95% CI 0.20 − 0.85). There were no differ-
ences in the number of platelet or red blood cells transfusions
administered. The association between ES and the use of ampho-
tericin B has been reported previously, and may reﬂect the com-
mon practice of administering amphotericin B for a new fever.
The prompt recognition of the ES may reduce the use of ampho-
tericin B in this setting and support the prompt administration of
steroids.
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AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELL TRANSPLAN-
TATION IN PATIENTS WITH GERM-CELL TUMORS
Nepomucka, J.1; Boublikova, L.1; Donatova, Z.1; Charvat, J.2; Kalanin,
J.2; Greplova, M.3; Bartova, M.1; Abrahamova, J.1 1. Thomayer
Memorial Teaching Hospital, Prague, Czech Republic; 2. Institute for
Clinical and Experimental Medicine, Prague, Czech Republic; 3.
Kralovske Vinohrady University Hospital, Prague, Czech Republic
Autologous peripheral blood progenitor cell rescue was provided
in our center from January 1998 to October 2000 to 19 patients
with relapsed or refractory germ-cell tumors. Median age was 28
years and tumor markers (AFP and/or HCG) were elevated in 6
patients at the time of high-dose chemotherapy.
Stem cell mobilisation was performed after 3rd cycle of VeIP
followed with ﬁlgrastim. The total amount of CD34+ cells/kg b.w.
was between 1.9 − 10.3 x 106 / kg . High-dose conditioning regi-
men CARBOPEC (carboplatin 1600 − 2200 mg / m2, etoposide
1800 mg / m2, and cyclophosphamide 6400 mg / m2, ) was used.
The treatment was well tolerated without any transplant − related
mortality.
The engraftment was rapid, recovery of hematopoiesis in neu-
trophils over 1.0 x 109 / l and platelets over 50 x 109 / l was reached
on the average on days + 10 nad + 13 respectively, using ﬁlgrastim
50g / kg beginning the day + 6. Using WHO criteria, non-hemato-
logical toxicity of therapy was predominantly of grade II.
The follow-up period is short, ranging from 3 to 30 month, but
at present 9 out of 19 patients are in CR, 2 pt are in SD and 8 pts
are dead. Two patients after autologous transplantation had
retroperitoneal lymphadenectomy, 3 pts received chemotherapy of
3rd line with paclitaxel and gemcitabine for relapse or persistence
of the disease. Patients are re-evaluated every 3 months during the
ﬁrst year and then after 4 − 6 months.
In conclusion, high-dose chemotherapy with autologous periph-
eral progenitor cell rescue in patients with advanced germ-cell
tumors is feasible and promising method of treatment in this
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group of patients and the evaluation of data conﬁrms the efﬁcien-
cy of autologous stem cell transplantation in patients with relapsed
or refractory germ-cell tumors.
34
RESOURCE UTILISATION AND COST OF PERIPHERAL BLOOD STEM
CELL COLLECTIONS IN HAEMATOLOGICAL MALIGNANCIES
O’Brien, M.1,2; Rowlings, P.A.2; Lindeman, R.2; McLachlan, A.J.1 1.
University of Sydney, Sydney, Australia; 2. Prince of Wales Hospital,
Sydney, Australia
The indications for PBSC collections and resource and cost
implications were analysed in a sequential cohort of 85 patients
with malignancy undergoing peripheral blood stem cell (PBSC)
collections at Prince of Wales Hospital from 1992 to 1999.
Resource utilisation was assessed by days in hospital, number of
aphereses, cost of pharmaceutical agents and other factors. The
observation interval began 4 weeks prior to start of agents used to
mobilize PBSC for collection up until 6 weeks after this date.
There were three indications for collection; planned transplant
(64%), back up collection in case of future transplant for relapse
or disease progression (29%) and randomised trial (7%). Patients
had a variety of haematological malignancies and solid tumours.
Various methods of stimulating patients for PBSC collections
were used including chemotherapy and growth factors (66%),
growth factor alone (16%) and other methods (18%). Median days
in hospital were 35 days for patients with acute lymphocytic
leukaemia (ALL), 23 days for AML, 15 days for seminoma and
CML, 12 days for MM, amyloidosis, HD, NHL, and rhab-
domyosarcoma, 7 days for neuroblastoma, 5 days for ovarian can-
cer, breast cancer and CML. 24% of patients required more than
one collection to achieve the minimum therapeutic CD34 cell
dose. The largest single contributor to cost in patients with breast
cancer, rhabdomyosarcoma, seminoma, MM, myeloﬁbrosis, neu-
roblastoma, NHL and ovarian cancer was the wholesale cost of
growth factor to pharmacy. In contrast in patients with ALL,
AML, CML, HD and amyloidosis the most expensive item was
bedstay cost.
Our study shows PBSC collections are performed for a wide
range of diseases and costs are driven by multiple factors. These
data show careful consideration of patient and treatment factors
are required to determine how PBSC collection impacts on overall
resource utilization in patients with malignancy.
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PERFORMANCE OF A VASCULAR ACCESS DEVICE (VAD) FOR LEUKO-
PHERESIS AND SUPPORT OF PATIENTS UNDERGOING AUTOLOGOUS
STEM CELL TRANSPLANTATION (APBSCT)
Restrepo, A.1; Devore, P.E.1; Encarnacion, C.E.1,2; Wholey, M.H.1,2;
Ferrao, H.1,2; Callander, N.S.1,2; Anderson, J.E.1,2; Przykucki, J.2; Pos-
toak, D.1,2; Freytes, C.O.1,2 1. UTHSCSA, San Antonio, TX; 2. South
Teaxs Veterans Health Care System, San Antonio, TX
Repeated blood sampling, procurement of peripheral blood stem
cells (PBSC) and the need to administer intravenous drugs make
vascular access a critical aspect in the supportive care of patients
undergoing APBSCT. In most institutions, two different catheters
are utilized in patients undergoing APBSCT, one for the pheresis
procedure and one for support during the transplant period. This
results in patient discomfort and increased cost since two catheters
have to be inserted. At our institution, we have utilized a central
venous triple-lumen silicone long-term access catheter for collec-
tion of PBSC and transplant support (Neostar®, Pheres-ﬂow®).
This catheter delivers adequate ﬂow rates for leukopheresis and is
also suitable for chemotherapy and ﬂuid infusions. The purpose of
this study was to analyze the performance of this catheter and
assess the feasibility of utilizing only one central VAD for collec-
tion of PBSC and transplant support. We prospectively analyzed
67 consecutive patients who underwent APBSCT between Janu-
ary 1999 and October 2000. Their median age was 54 (22-74) and
92 % were men. There were no complications related to insertion
of the catheter. The median duration of insertion was 33 days
(range 12-112). Reasons for removal of the catheter included:
completion of treatment in 53 pts. (79%), infection or suspected
infection 11 pts. (16%), three catheters were accidentally pulled
by the pts. (3%) and one catheter was removed because of a tear in
one of the ports (< 2%). Ten pts. required insertion of another
catheter to complete treatments related to APBSCT (4 Neostar®
and 6 other VAD). We conclude that collection of PBSC and
transplant support can be accomplished with one VAD in the
majority of patients. It is likely that this approach resulted in sub-
stantial savings since only 15% of patients required insertion of
another VAD to complete treatments related to APBSCT.
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EX-VIVO PROTECTION OF HEMATOPOIETIC STEM CELLS BY AMIFOS-
TINE BEFORE PURGING OF CONTAMINATING TUMOR CELLS WITH
MAFOSFAMIDE
Sumerauer, D.1; Kavan, P.1,2; Matejckova, S.1; Hruba, A.1;
Eckschlager, T.1; Kobylka, P.1; Stankova, J.1 1. Faculty Hospital Motol,
Prague, Czech Republic; 2. Montreal Childrens Hospital, Montreal,
PQ, Canada
We have studied the effects of Amifostine (WR-2721, Ethyol)
on the cytotoxicity of mafosfamide in normal bone marrow and
peripheral blood progenitor cells and malignant cells derived from
tumor cell lines originating from neuroblastoma and Ewing sarco-
ma in an experimental model of ex vivo purging. Low amounts of
tumor cells were diluted into the mononuclear cells fraction
obtained from PBSC or BM of the healthy donors (4) and one
patient with acute myeloid leukemia.
Objectives: To evaluate the protective efficiency of amifostine
pretreatment on progenitor cells, to evaluate the ability of mafos-
famide to eliminate present contaminating malignant cells .
Methods: Hematopoietic cells containing contaminating tumor
were incubated 30 min at 37°C in the presence of mafosfamide
(100 ug/ml) alone, amifostine alone (4 mg/l, 15 min incubation) or
in mafosfamide after amifostine pretreatment. Presence of tumor
cells was detected using FISH (neuroblastoma) or RT-PCR
(Ewing sarcoma) with a subsequent testing of tumor cell viability
when manufactured under the same conditions described. Progen-
itor cells ( CD 34+) were calculated by ﬂow cytometry. Progenitor
clonogenic assay was made after a short cultivation and recovery
of progenitor colony forming units, CFU-GM and BFU-E was
than scored.
Results: Although contaminating tumor cells were still
detectable after mafosfamide treatment with FISH and RT-PCR
technics, the significant decrease in tumor cell viability was
observed after a short cultivation. There were no demonstrable
amifostine protection of malignant cells in the study and no signif-
icant change in CD 34+ cells count.
Conclusion: We can summarize that mafosfamide treatment led
to two - three fold depletion of contaminating tumor cell while
pretreatment with amifostine preserved acceptable ammout of
hematopoietic progenitors. These ﬁndings suggest that amifostine
and mafosfamide combination should have therapeutic vallue dur-
ing ex vivo purging of bone marrow for autologous bone marrow
transplant.
Supported by grant IGA MZ CR No:5036
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FLT3 LIGAND HEMATOPOIETIC AND IMMUNE ACTIVITY IN MICE IS
DEPENDENT ON FORMULATION OR DURATION OF ADMINISTRATION
Talmadge, J.E.1; Robinson, S.1; Rosenthal, G.2; Blonder, J.2; Chavez,
J.1; Mosley, R.1 1. University of Nebraska Medical Center, Omaha,
NE; 2. RxKinetix, Louisville, CO
In mice treated with 10 µg of FL for 10 days, the frequency and
absolute numbers of dendritic cells (DCs), including type 1 DC
(DC1) and type 2 DC (DC2) subsets, are elevated with DC1s
preferentially expanded. In contrast, the frequency of B and T
cells are either diminished or unchanged, whereas their total num-
bers are signiﬁcantly increased in spleen and PB. Moreover, in the
spleens of FL-treated mice, IFN-secreting cells are increased 8.1-
fold compared to a 1.9-fold increase in IL-4 producing T cells.
Further, the mitogenic responses of spleen cells from the FL-
treated mice were signiﬁcantly increased. As previously reported
CD34+ cells and CFU-GM are also increased in the PB, spleen
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and BM. However, in the absence of prolonged FL administration
minimal effects on hematopoiesis occurs. FL formulation within a
poloxamer-based matrix ProGelZ (PGZ) accelerates mobilization
of hematopoietic progenitor cells (CFU-GM and HPP-CFC).
Within 3-4 days, one dose of FL/PGZ (15 µg/animal) induced a
signiﬁcant increase in the frequency and total numbers of CFU-
GM and HPP-CFC, whereas a 3-day regimen of a saline-formu-
lated FL (5 µg/day and 15 µg/animal) induced little hematopoietic
activity. Within the bone marrow, FL/PGZ signiﬁcantly increased
the frequency and number of CD34+ and CD34+CD49d+ (VLA-
4+) cells, whereas saline-formulated FL had little effect on these
subsets. In PB, the frequency and number of granulocytes and
CD34+ cells were signiﬁcantly increased by 3 days after FL/PGZ
treatment, whereas increases in Gr-1+ cells were not detected and
lymphocyte number and frequency were decreased. In contrast,
FL/PGZ significantly increased the frequency and number of
Gr-1+ spleen cells. These data indicate that accelerated mobiliza-
tion of hematopoietic progenitors occurs with the use of a
FL/PGZ formulation. Supported by NIH grant AI42722.
AUTOIMMUNE
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RELAPSE OF SLE AFTER AUTOLOGOUS STEM CELL TRANSPLANTA-
TION (ASCT): NO RESPONSE TO CONVENTIONAL THERAPY
Arnold, R.1; Rosen, O.1; Massenkeil, G.1; Radtke, H.1; Gromnica-Ihle,
E.2; Hiepe, F.1; Burmester, G.1; Thiel, A.3; Radbruch, A.3 1. University
Hospital, Charite, Berlin, Germany; 2. Clinic for Rheumatology,
Berlin, Germany; 3. German Research Center for Rheumatology,
Berlin, Germany
3 patients with severe systemic lupus erythematodes (SLE)
refractory to conventional therapy underwent intensive
immunoablation (in vivo and ex vivo purging) and ASCT. Remis-
sion of disease occurred in all 3 patients. Autoantibody titers dis-
appeared and were below cut-off.
2 of 3 patients are still in remission (30, resp. 27 months after
ASCT), one patient relapsed 17 months after ASCT. This male
patient relapsed with a nephrotic syndrome, skin and mucous
membrane involvement. Very high levels of autoantibodies were
demonstrated and a broader spectrum of autoantibodies was
involved than before ASCT. The patient received high dose
methylprednisolone and 3 courses of cyclophosphamide pulse, but
failed therapy. Because of acute renal failure dialysis was per-
formed. A kidney biopsy was performed to decide, whether fur-
ther immunosuppressive therapy might be indicated, and revealed
active glomerulonephritis.
We started an experimental therapy approach with ﬂudarabine
and antilymphocyte globulin for remission induction and plan to
retransplant the patient from an allogeneic stem cell donor.
Our data indicate that in advanced stage SLE lymphocyte clones
are resistant to immunoablation and ASCT. After a further expan-
sion due to unknown stimuli, a broad spectrum of autoantibodies
was produced, leading to clinical relapse.
CHRONIC LEUKEMIA
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COMPARABLE SURVIVAL FOR NONABLATIVE AND ABLATIVE ALLO-
GENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA
(CLL): THE CASE FOR EARLY INTERVENTION
Khouri, I.F.; Munsell, M.; Yajzi, S.; Giralt, S.; Korbling, M.; Ippoliti,
C.; Donato, M.; Keating, M.; Champlin, R. Univ. of Texas M.D.
Anderson Cancer Center, Houston, TX
Allotransplant has been investigated for CLL over the past
decade. The following is an update of our experience. Forty
patients were treated. Patients were eligible if they failed ﬂudara-
bine. Since 1995, patients >50 years or with comorbidities were
eligible for nonablative stem cell transplantation (NST). Median
age was 48 years (range 26-67 years). Twenty-seven patients
(67.5%) had Rai III-IV disease. The median number prior to
chemotherapy regimens was 3 (range 1-8). Twenty-six patients
(67%) were chemorefractory. The preparative regimen consisted
of Cy/TBI or fludarabine (90mg/m2)/cyclophosphamide (2250
mg/m2) over 3 days for those who received NST. With a median
follow-up time of 40 months (range 3.5-105 months), overall sur-
vival (OS) at 3 years was 47% (95% CI=33-68), and disease free
survival (DFS) was 34% (95% CI=22-54). On univariate analysis,
the following was found to be important prognostic factors at 3
years: 1) Sensitive vs. refractory disease: OS 73% vs. 32% respec-
tively (P=0.03), DFS 64% vs. 22% (P=0.01); 2) Diploid vs. abnor-
mal cytogenetics: 62% vs. 10% respectively (P=<0.01), DFS 36 vs.
8% (P=0.01); 3) Presence or absence of paraimmunoblasts: OS
60% vs. 33% respectively (P=0.17), DFS 51% vs. 14% (P=0.03);
4) Number of prior regimens is less or more than 2: OS 67% vs.
32% respectively (P=0.05) and DFS 60% vs. 18% (P<0.01).
Eleven patients received NST. Prognostic characteristics were
equally distributed between the NST and the HDCT arms, but
there was a signiﬁcant difference in age (median 57 vs. 43 years
respectively, P<0.01). Toxicity was much reduced with NST and
there was no difference in OS (53% for NST, 48% for HDCT).
These data suggest that patients transplanted earlier in the course
of the disease appear most likely to beneﬁt. NST appears promis-
ing and should be further evaluated in younger patients who are
early in the course of the disease.
GVH/GVL
40
SEROLOGIC IDENTIFICATION OF MINOR HISTOCOMPATIBILITY
ANTIGENS
Miklos, D.B.; Wu, C.J.; Soiffer, R.J.; Antin, J.H.; Ritz, J. Dana-Far-
ber Cancer Institute, Boston, MA
Graft-versus-host disease (GVHD) is a major cause of morbidity
and mortality associated with allogeneic hematopoietic stem cell
(HSC) transplantation, and is initiated by alloreactive donor T-
cells that recognize recipient minor histocompatibility antigens
(mHA) presented in an HLA restricted fashion. Clinical insight,
improved donor/recipient matching, and therapeutic options are
currently limited by the few number of mHA identiﬁed thus far.
Seeking a rapid and efﬁcient method to identify mHA, we hypoth-
esized that the immunogenicity of mHAs results in a humoral B-
cell response in addition to the T-cell recognition.
Preliminary studies to test the humoral response hypothesis
focused on sex-mismatched allogeneic transplantation, thereby
providing a limited patient population with high GVHD risk, and
many previously identified H-Y antigens. The serum of six sex-
mismatched male GVHD patients was tested for speciﬁc antibody
recognition to three recombinantly expressed H-Y antigens
(UTY, DBY, and EIF-1AY), and HA-1. Remarkably, four out of
six male sera recognized at least one of the four mHA tested, and
this mHA reactivity was absent prior to transplant (see table). Our
preliminary studies demonstrate humoral immune recognition for
mHA thereby suggesting SEREX screening with GVHD serum
may rapidly identify mHA, and ultimately allow mHA typing
prior to HSC transplantation.
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METRONIDAZOL IN COMBINATION WITH CIPROFLOXACIN COMPARED
TO CIPROFLOXACIN ALONE AS INTESTINAL BACTERIAL DECONTAMI-
NATION: NO EFFECT ON THE INCIDENCE OF ACUTE GVHD
Aschan, J.; Remberger, M.; Ljungman, P.; Löfgren, C.; Hentschke, P.;
Ringdén, O. Karolinska Institutet, Stockholm, Sweden
Thirty-eight consecutive patients undergoing allogeneic
stem cell transplantation were given metronidazol 400 mg
TID until day +60 and compared to 38 matched historical
controls not given metronidazol. All patients received oral
ciprofloxacin 500 mg bid. Diagnoses included AML (9), ALL
(9), CML (7), CLL (1), MDS (4), NHL (2), myeloma (1),
myelofibrosis (1), SAA (2) and inborn errors of metabolism (2).
Donors were HLA-identical siblings (18), MUD (19) or mis-
matched related (1). Median patient age was 31.5 (range 0-60)
and there was 23 males and 15 females. Among patients with
hematological malignancies 20 patients were in first CR or CP
while others were in more advanced stages. GVHD prophylax-
is consisted of MTX+CSA (34), MMF+CSA (3) or T-cell
depletion (1). Controls were matched for age, gender, diagno-
sis, type of donor and GVHD prophylaxis. Twenty-five
patients received PBSC vs 17 in the control group (ns) and 38
received post-transplant G-CSF compared to 31 (p=0.01).
This resulted in a higher stem cell dose, 8.0 vs 3.8 x 106
CD34+ cells/kg (p=0.04) and a shorter time to ANC >0.5 x
109/L, 12 vs 15 days (p=0.006). Nine patients (24%) receiving
metronidazol developed acute GVHD grade II-IV compared
to 7 patients (18%) in the control group (ns). TRM day +100
was 11% vs 8% (ns) and short term patient survival 89% in
both groups.
Conclusion: Metronidazol added to ciprofloxacin as bacterial
decontamination compared to ciproﬂoxacin alone did not decrease
the incidence of acute GVHD or reduce TRM at day +100.
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DEPLETION OF CD8+ T CELLS FROM DONOR BLOOD BUFFY COATS
FOR LOW DOSE CD4+ T CELL DONOR LEUKOCYTE INFUSIONS (DLI)
USING THE CD8-HDM CELL SEPARATION SYSTEM
Houde, H.; Schmittling, R.; Zhu, H.; Cook, D.; Monroy, R. Eligix, Inc,
Medford, MA
Donor leukocyte infusions (DLI) are being utlized more fre-
quently to enhance the GvL effect and to prevent leukemic
relapse after patients have received an allogeneic stem cell graft.
Investigators have reported using multiple T-cell infusions rang-
ing from 5 x 105 to 5 x 108 cells/kg. It is anticipated that trans-
plantation centers will attempt to utilize units of donor blood as
the source of T cells eliminating the need for an apheresis prod-
uct. However prior to infusion, an increasing number of DLI
products are purged of CD8+ T cells to reduce the incidence of
acute GvHD. We evaluated the CD8-HDM Cell Separation
System to deplete CD8+ T cells from buffy coat preparations.
Antibody coated high density microparticles (HDM) effect cell
separation. Buffy coats (45-50mL) were adjusted to 150mL with
saline 1% HSA, transferred to a depletion chamber containing
CD8-HDM and rotated for 10 minutes. The chamber was
stopped in an upright position allowing the HDM and captured
CD8+ T cells to settle. Cells in the supernatant were transferred
to a second depletion chamber and the process was repeated for
a total of 3 depletion cycles. Buffy coats products (N=5,
mean=1.9 x 109 nucleated cells) were processed containing an
average 7.6% CD8+ and 24.6% CD4+ T cells. Mean percent
hematocrit and platelet count in the processed product were
27.3% and 4.4 x 105/µL, respectively. Median values for deple-
tion of CD8+ T cells was 98.3% (95-99.8%) and recovery of
CD4+ T cells was 74.5% (44-81%). The ﬁnal products averaged
3.3 x 108 CD4+ T cells, enough T cells to infuse a 70kg recipient
with greater than 4 x 106 CD4+ cells/kg. This study demon-
strates that the CD8-HDM Cell Separation System can be used
to deplete CD8+ T cells from donor buffy coat cells to enable
low dose CD8 depleted DLI.
HISTOCOMPATIBILITY/ALTERNATIVE
STEM CELL SOURCES
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HIGH VOLUME LEUKAPHERESIS INCREASES CD34+ YIELD FROM
PERIPHERAL BLOOD
Dozier, M.M.; Livingston, D.L.; Dicke, K.A. Arlington Cancer Center,
Arlington, TX
A total of 159 high volume (18-21 liter) leukapheresis proce-
dures on 75 unselected patients (65 solid tumors and 10 hemato-
logical malignancies) were analyzed for efﬁcient collection of cir-
culating CD34+ progenitor cells. Regardless of the mobilization
regimen, 5 or 10µg/kg G-CSF x 6 days, standard dose chemother-
apy with 5ug/kg G-CSF or Cytoxan/Taxol/SCF + G-CSF, col-
lecting >18L yielded a median recovery of 151% (25-333%) of the
available CD34+ cells. Solid tumor patients recovered a slightly
higher percentage of circulating progenitor cells versus hemato-
logical malignancies (median of 151% vs 136%), but this could be
due to the difference in patient number (65 solid vs 10 hematolog-
ical malignancies). Cytoxan/Taxol/SCF + G-CSF mobilization (6
patients; 9 procedures) was comparable with a median recovery of
152%, consistently collecting more CD34+ progenitor cells than
expected with an efficient range of 119-270%. Flow cytometric
analysis of CD34+ cells was performed on the end product of an
18-21 Liter collection from the Cobe Spectra or Fenwal CS3000.
The increase in recovery was independent of the instrument, the
speed of collection (85 ml/min on the CS3000 vs. 135 ml/min on
the Spectra), or the mobilization regimen. Patients tolerated high
volume leukapheresis well, with no adverse events during the pro-
cedure. Electrolytes were continually administered with fluids
intravenously during the procedure to suppress citrate toxicities.
This apparent secondary mobilization may be caused by the dyse-
quilibrium created when the circulating pool of progenitor cells
has been depleted from the circulation, which promotes further
movement of progenitor cells from the marrow cavity to the
peripheral blood.
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ANALYSIS OF THE DONOR SEARCH PROCESS FOR UNRELATED STEM
CELL TRANSPLANTATION IN KOREA
Kim, D.; Min, C.; Lee, S.; Kim, K.; Lim, J.; Cho, B.; Lee, J.; Min,
W.; Kim, H.; Kim, C. Catholic Hemopoietic Stem Cell Transplantation
Center, The Catholic University of Korea, Seoul, South Korea
Since two Korean registries for registration of unrelated bone
marrow donors established in 1994, we performed ﬁrst unrelated
donor transplant in 1995. In present study, the search process
within the last two years for an unrelated donor at the Catholic
University of Korea is analyzed.
Between 1998 and 1999, the search for an unrelated donor for
287 patients was performed. Low resolutional HLA-A and -B typ-
ing was performed by serology and HLA-DRB1 typing was done
by DNA-typing. With 287 patients initiated for search, we ana-
lyzed match rate, the intervals between search activation and trans-
plant, and coordination success rate. We also analyzed the results
of donor search process through the Japan Marrow Donor Pro-
gram and Tzu-Chi Taiwan Marrow Donor Registry (TCTMDR).
At least one HLA-identical donor has been found for 54.7% of
287 patients in the ﬁrst search after the patients register with the
KMDP and CHIB, As of the end of July 2000, 53 patients (18.5%)
had received unrelated bone marrow transplants and the coordina-
tion success rate was 33.8% (53/157 patients). The average inter-
val between initial search and transplant with the Korean reg-
istries was 128 days (61-208 days). Among 47 patients who
registered in the JMDP, 25 patients (53.2%) found at least one
HLA-identical donor. Twelve of them (48%) were transplanted.
The average time to transplants was 149 days (112-207 days).
Since January 2000, we have registered 22 patients to search unre-
lated donor in the TCTMDR. Four of them (18.2%) had one
HLA-matched donor and transplants are now in progress.
The Korean unrelated donor pool is rapidly expanding and the
patients who receive unrelated transplant are also increasing in
Korea. From these data, we realized that the international network
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of donor and transplant centers of Asian countries would be very
important for facilitating unrelated donor transplants for patients
who could not ﬁnd suitable donor in their national registries.
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SUCCESSFUL GRAFT VERSUS HOST DISEASE (GVHD) PROPHYLAXIS
USING TACROLIMUS AND MYCOPHENOLATE MOFETIL (MMF) IN AN
ADULT PATIENT UNDERGOING MISMATCHED UNRELATED DONOR
CORD BLOOD TRANSPLANTATION (UD-CBT)
Nath, R.; Janakiraman, N.; Fortney, C.; Al-Janadi, A.; Burt, S.;
Ford-Cattaneo, C.; Green, J.; Kukuruga, D.; Shurafa, M.; Chapman,
R. Henry Ford Health System, Detroit, MI
UD-CBT is a curative therapy in patients with hematologic
malignancies but concerns about its engraftment capacity and
delayed engraftment has limited its use in heavier adults. Standard
GVHD prophylaxis regimens either contain methotrexate, which
further delays engraftment, or high-dose steroids which predis-
poses for infection in a setting of delayed engraftment.
We report a 37 year old male (weight 80 kg), with acute myeloid
leukemia in third CR, who underwent a successful one antigen
mismatched (HLA-B locus) UD-CBT using Tacrolimus and
MMF for GVHD prophylaxis. Patient was conditioned with
thiotepa 750 mg/m2, busulphan 12 mg/kg, cyclophosphamide 120
mg/kg and horse ATG 20 mg/kg for two doses. 1.48 x 107 nucle-
ated cells/kg (4.3 x 105 CD34 cells/kg) from one antigen mis-
matched unrelated cord blood were infused after thawing, utiliz-
ing the New York blood bank method. GVHD prophylaxis
consisted of MMF 1000 mg iv/po every 12 hours from day -1 to
30 and Tacrolimus (levels 5-20 ng/ml) from day -1 with a taper
beginning at three months. Low dose Solu-Medrol was required
for allergic reaction to ATG and hand-foot syndrome (0.5 mg/kg
day 1 to 4, 0.25 mg/kg day 5 to 20 and tapering off at day 25).
Ciproﬂoxacin, acyclovir, ﬂuconazole and Pentamidine were used
for bacterial, viral, fungal and PCP prophylaxis respectively.
Grade II mucositis developed which healed before day 30.
Engraftment of neutrophils (>500/µl) occurred on day 22 and
absolute neutrophil count reached >1000/µl on day 24. Platelet
count >20,000/µl was reached on day 64 and platelet count
>50,000/µl on day 79. There was no acute GVHD. Bone marrow
aspirate and biopsy done on days 30 and 100 post transplant
revealed 100% donor chimerism with no evidence of acute
leukemia.
Conclusion: Tacrolimus and MMF resulted in timely engraft-
ment and successful GVHD prophylaxis without signiﬁcant toxici-
ty in an adult undergoing mismatched UD-CBT.
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NO STABLE MIXED CHIMERISM AND POOR IMMUNE RECONSTITU-
TION AFTER MAJOR HLA MISMATCHED T-CELL DEPLETED ALLO-
GENEIC AND AUTOLOGOUS STEM CELL TRANSPLANTATION
Ringdén, O.1; Mattsson, J.1; Uzunel, M.1; Tammik, C.1; Omazic, B.1;
Levitsky, V.2; Zou, J.2; Hentschke, P.1; Remberger, M.1 1. Huddinge
University Hospital, Stockholm, Sweden; 2. Karolinska Institutet,
Stockholm, Sweden
Two adults with primary liver cancer underwent liver transplan-
tation from 5/6 and 4/6 major HLA-antigens mismatched unrelat-
ed donors. They were then conditioned with 4 x 2 Gy TLI, 120
mg/kg cyclophosphamide, 7.5 Gy TBI and ATG. Thereafter, the
patients received T-cell-depleted autologous : unrelated mis-
matched bone marrow in a proportion of 0.5:3.0 and 0.35:1.1 x
106 CD34+ cells/kg, respectively. After stem cell transplantation
(SCT), both became mixed chimeras, as determined with PCR
ampliﬁcation of variable number tandem repeats. Due to a reduc-
tion in donor T-cells, the first patient was given 105 donor T-
cells/kg and became a complete donor chimera within three
months. The second patient rejected all donor cells within 1
month after SCT. WBC normalized in both patients within 1
month. CD8+ cells normalized after 4 and 2 months in the two
patients, respectively. However, CD4+, CD56+ and CD19+ cells
remained low, except for a transient increase in patient no. 2.
Lymphocyte responses to mitogens were negative in patient 1
from 1-5 months after ASCT. This patient also showed an oligo-
clonal pattern of the B-cell repertoire, performed by CDR3 spec-
tratyping. EBV DNA in lymphocytes increased by 4-5 log in both
patients. Prior to SCT, recipients and donors were mutually reac-
tive in MLC. In the first patient, the chimera cells showed no
response to recipient or donor, but a positive response to third
party. In the other patient, recipient cells reacted vigorously
against donor lymphocytes at the time of rejection. Both patients
suffered from overwhelming bacterial, fungal and viral infections,
and died of pneumonia 5 and 3 months after ASCT, respectively.
To conclude, with a major HLA-mismatch barrier, stable mixed
chimerism seems difﬁcult to achieve. The ﬁrst patient became a
full donor chimera and the second one rejected the graft. Both
suffered from immune incompetence.
LATE EFFECTS
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INFECTION CONTROL AND VACCINATION PRACTICES AT U.S. AND
CANADIAN BLOOD AND BONE MARROW TRANSPLANT CENTERS, 2000
Ostrowsky, B.1; Rizzo, J.2; Horowitz, M.2; Jarvis, W.1; Pearson, M.1 1.
Centers for Disease Control and Prevention (CDC), Atlanta, GA; 2.
IBMTR/ABMTR, Milwaukee, WI
Introduction: Infections are important causes of morbidity and
mortality in blood or bone marrow transplant recipients. Howev-
er, there are few national data on infection control and vaccination
practices at transplant centers.
Methods: In February and April 2000, the IBMTR/ABMTR
mailed a survey to member transplant centers in North America.
Results: Overall, personnel at 96/232 (41%) centers in 32 U.S.
states and 9 Canadian Provinces responded. All centers performed
autologous transplants. Fewer performed other transplant proce-
dures [allogeneic-related transplants (72), allogeneic-unrelated
transplants (55), or umbilical cord blood transplants (39)]. Ninety-
three responding centers reported doing transplants for hemato-
logical malignancies, 65 for non-malignant hematologic disorders,
89 for solid organ malignancies, 36 for immune disorders, and 26
for autoimmune disorders. Seventy-three (76%) centers had a sep-
arate transplant unit. Nearly all (>90%) centers limited transplant
recipient exposure to plants, visitors with upper respiratory tract
infections, or crowded places. In contrast, there was wide variation
in restricting transplant recipient exposure to showering (15%),
use of tap water (38%), young visitors (57%), carpets (74%),
humidiﬁers (76%), or fruits/vegetables (81%). At 72 (75%) cen-
ters all patients are treated in high efficiency particulate air
(HEPA)-ﬁltrated rooms. Only 29 (30%) centers placed transplant
patients in laminar ﬂow rooms. Twenty-seven (28%) centers did
not have policies for routine vaccination of transplant recipients,
of which 9 performed autologous transplants only.
Conclusions: These ﬁndings document wide variation in infec-
tion control and vaccination practices at blood and bone marrow
transplant centers. Some practices are not consistent with the
recent CDC Guidelines for Preventing Opportunistic Infections
Among Hematopoietic Stem Cell Transplant Recipients. Trans-
plant directors may wish to review these guidelines and their cen-
ter′s infection control and vaccination practices to insure that
infection prevention is optimized. These data may serve as a base-
line for assessing the impact of the new CDC guideline on infec-
tion prevention.
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B-LYMPHOPOIESIS IS INHIBITED IN PATIENTS WITH GRAFT-VS-
HOST DISEASE (GVHD)
Storek, J.1; Wells, D.2; Dawson, M.A.1; Storer, B.1; Maloney, D.G.1 1.
Fred Hutchinson Cancer Research Center, Seattle, WA; 2. Hematolog-
ics, Inc., Seattle, WA
Hematopoietic cell transplant recipients suffer from frequent
infections due in part to quantitative B cell deﬁciency. In 93 allo-
graft recipients, the quantity of marrow B cell precursors on day 80
and 365 correlated with the counts of circulating B cells, which
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strongly suggests that the B cell deﬁciency is due at least in part to
insufficient B-lymphopoiesis. We evaluated which factors might
hamper the B-lymphopoiesis. The quantity of marrow B cell pre-
cursors on day 80 was 35-fold higher in patients who did not devel-
op grade 2-4 acute GVHD compared to patients who developed it.
Similarly, the quantity of B cell precursors on day 365 was 22-fold
higher in patients who did not develop clinical extensive chronic
GVHD compared to patients who developed it. The quantity of B
cell precursors was not related to CD34 cell dose, type of trans-
plant (marrow vs blood stem cells), donor age or patient age. We
conclude that posttransplant B cell deﬁciency results in part from
GVHD-associated inhibition of B-lymphopoiesis.
LYMPHOMA
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UPDATED ANALYSIS OF PATIENTS WITH NON-HODGKIN’S LYM-
PHOMA RECEIVING EITHER ALLOGENEIC OR AUTOLOGOUS TRANS-
PLANTS OVER A 12 YEAR PERIOD
Dansey, R.D.1; Abella, E.1; Karanes, C.1; Klein, J.1; Hamm, C.1; El-
Rayes, B.1; Baynes, R.D.1 1. Barbara Ann Karmanos Cancer Institute
and Wayne State University, Detroit, MI; 2. National Marrow Donor
Program, Minneapolis, MN
Two hundred twenty two patients with non-Hodgkin’s lym-
phoma have undergone either bone marrow or peripheral blood
stem cell transplantation from 1987 to the present at our institu-
tion. One hundred thirty eight were male and 84 were female with
a mean age of 43 years with the oldest patient being 68 years.
Autologous transplants were performed in 144 (63%) patients,
allogeneic transplants in 79 (36%) and syngeneic transplants in 2
(1%) patients. Pre-transplant disease status included complete
remission in 44 patients, partial remission in 81 patients, progres-
sive disease in 44 patients, relapsed disease with chemotherapy
sensitivity undeﬁned in 43 patients, stable disease in 4 patients and
unknown in 6 patients. Conditioning regimens included CY/TBI
in 155 patients and CVB in 48 patients with other combinations in
19 patients. Relapse has occurred in 66 (30%) patients and 123
(55%) patients have died. Of the 73 deaths in the autologous
transplant patients, 40 died from progressive disease. In contrast,
of the 49 deaths in the allogeneic transplant patients, only 9 died
from progressive disease. Ninety nine (45%) patients were alive at
last follow-up with a median survival of 1.4 years and the longest
survivor at 10 years. There are 25 patients alive and well beyond
4.7 years, 12 of whom received allogeneic transplants and 18
autologous transplants. Despite the lower relapse rate in allogene-
ic transplant patients there appear to be no signiﬁcant differences
in event free or overall survival between autologous and allogeneic
transplant patients. Transplantation with either approach appears
to be durable in a proportion of patients. Detailed information is
being sought on the longest survivors and will be presented.
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A PROSPECTIVE, COMPARATIVE TRIAL OF ALLOGENEIC VS AUTOLO-
GOUS STEM CELL TRANSPLANTATION FOR HIGH RISK LYMPHOMA:
INTERIM ANALYSIS
Goldstein, S.; Perkins, J.; Janssen, W.; Field, T.; Partyka, J.;
Loughran, T.; Djulbegovic, B.; Sullivan, D.; Reimer, D.; Fields, K. H.
Lee Mofﬁtt Cancer Center and Research Institute at the University of
South Florida, Tampa, FL
Relapse after High Dose Therapy (HDT) and autologous stem
cell transplantation (SCT) remains one of the major obstacles to
improving overall outcomes for high risk lymphoma patients (pts).
Retrospective studies of autologous vs. allogeneic SCT have
strongly suggested the relevance of a ‘graft vs lymphoma’ (GVL)
effect on lowering the relapse rate (RR) after allo SCT but the
reduction in RR has not yet translated into improved overall sur-
vival (OS) or event-free survival (EFS) due to the higher treatment
related mortality (TRM) of allo SCT. No prospective trial com-
paring auto to allo SCT while controlling for the important vari-
ables which confound the interpretation of the retrospective series
has been reported. We report the interim results of an ongoing
trial of auto vs allo SCT following CBV (Cytoxan, BCNU,
Etoposide)for adult patients with Non-Hodgkin’s Lymphoma
(NHL) or Hodgkin’s Disease (HD)who had either relapsed or
failed to achieve remission with standard induction. Pts were
‘genetically’ randomized based on availability of an HLA-identical
sibling donor for all patients who were eligible for standard allo
transplantation. To date, 76 pts have undergone HDT/SCT: auto
n=57(28 NHL, 29 HD); allo n=19(15 NHL, 4 HD). By stem cell
source (auto v. allo), OS, EFS, FFP, and 100d TRM are 62+/-8%,
50+/-8%, 58+/-9%, and 9%, respectively for auto pts; vs. 49+/-
12%, 43+/-12%, 72+/-12%, and 26% for allo pts. Death from
progressive disease accounts for 12/17 (71%)among auto patients
vs 2/9 (22%)among allo pts. To date, there have been no ‘late’ (>6
months post transplant)relapses among the 10 allo pts surviving
beyond 6 months, with 3 pts beyond 3 years; whereas relapse con-
tinues late post transplant among auto pts, strongly suggesting the
beneﬁt of immunosurveillance achieved with allotransplantation.
Further accrual and follow-up is required to determine if this
improved FFP will translate into an OS advantage for standard
allotransplantation.
51
THE B CELL-HDM CELL SEPARATION SYSTEM DEMONSTRATES
GREATER THAN A FOUR LOG DEPLETION OF CD20+ B CELLS WITH
A HIGHLY REPRODUCIBLE RECOVERY OF CD34+ AND CD3+ CELLS
Houde, H.; Zhu, H.; Schmittling, R.; Graney, M.; DeLucia, D.; Cook,
D.; Monroy, R. Eligix, Inc, Medford, MA
Immunomagnetic cell selection devices are available that isolate
CD34+ cells from mobilized peripheral blood stem cell (PBSC)
collections for subsequent infusion after high dose chemo/radia-
tion therapy. As a consequence of the selection process, contami-
nating tumor cells may be reduced in the autograft. However,
such a selection process often results in a signiﬁcant loss of stem
cells, depletion of T cells and accessory cells, and may leave cells
coated with antibody. As a result, multiple studies have document-
ed a pronounced immunodeficiency in some patients who were
infused with CD34 selected autologous stem cells. A functionally
closed B Cell-HDM Cell Separation System has been developed
to effectively purge CD19+ and CD20+ tumor cells from autolo-
gous PBSC of patients with non-Hodgkins lymphoma (NHL)
with minimal stem cell loss. This system utilizes antibody coated
high density microparticles (HDM) to selectively purge CD19+
and CD20+ B cells from PBSC. To assess the performance of this
system, G-CSF mobilized apheresis products from normal volun-
teers (N=22) were processed in a simulated clinical setting.
CD20+ B cells post processing were detected using an immunocy-
tochemistry assay and an Automated Cellular Imaging System.
Mean CD20+ B cell depletion was 4.9logs +/-0.8logs. CD34 fre-
quencies were measured in 2 separate labs and values were aver-
aged to obtain the %CD34 recovery for each donor. Based upon
the average values, the median %CD34+ cell recovery was 92%
(range: 63% to 139%). Median CD3+ T cell recovery was 95%
(range: 73% to 125%). A median of 3.2 x 1010 nucleated cells
(range 1.7-6.2 x 1010 cells) were processed without interference
from contaminating RBC and platelets. This study reproducibly
demonstrated a signiﬁcant depletion of CD20+ B cells with highly
efﬁcient recoveries of CD34+ and CD3+ cells. The system will be
implemented in a pivotal clinical trial to purge B cells from PBSC
of NHL patients.
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A TEN YEAR, SINGLE CENTER STUDY OF TRANSPLANTATION IN
RELAPSED FOLLICULAR NON-HODGKIN′S LYMPHOMA
Sabloff, M.; Morrin, S.M.; McDiarmid, S.A.; Bence-Bruckler, I.;
Atkins, H.L.; Bredeson, C.N.; Genest, P.; Perry, G.A.; Huebsch, L.B.
University of Ottawa, Ottawa, ON, Canada
We report on the long-term results of 175 transplants in
patients aged 22 to 65 with relapsed FL who underwent either an
autologous marrow or stem cell transplant (autoBMT) or an allo-
geneic CD34-selected matched sibling marrow (alloBMT)
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between 6/90 and 8/00. Of these, 122 had chemotherapy-sensitive
FL (FL-CS), 21 had transformed FL (FL-T) and 12 had
chemotherapy-insensitive FL (FL-CIS). 20 alloBMT were per-
formed. FL-CS patients and alloBMT patients received melphalan
(140 mg/m2), VP-16 (60 mg/kg) and 500 or 1200 cGy TBI. FL-T
patients received BEAM. Unpurged BM, stem cells or both sup-
ported the autoBMT patients.
With a median follow-up of 4.5 years, the FL-CS pts. had a 6-
year overall survival (OS) of 74% (95% CI: 69 − 79%) and a pro-
gression-free survival (PFS) of 57% (95% CI: 52 − 62%). Of the
25 deaths in this group, 12 were due to lymphoma, 5 to transplant
toxicities and 8 to other causes. Late complications have included
3 cases of MDS and 2 cases of carcinoma. The 3-year PFS
between autoBMT for FL-CS and alloBMT was not signiﬁcantly
different; however, the 3-year overall survival between these two
groups favored autoBMT.
Our data demonstrate that unpurged autoBMT for patients with
relapsed, FL-CS is safe and can result in a high long-term OS and
PFS. AutoBMT of both FL-CIS and FL-T yielded poorer OS and
PFS. AlloBMT for FL demonstrates a poorer survival curve at 3
yrs in part due to higher early mortality.
MULTIPLE MYELOMA
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MAINTENANCE THERAPY WITH INTERFERON FOLLOWING AUTOLO-
GOUS PROGENITOR CELL TRANSPLANTATION IN PATIENTS WITH
MULTIPLE MYELOMA
Cogle, C.R.; Moreb, J.S.; Boyette, R.M.; Leather, H.L.; Finiewicz,
K.J.; Khan, S.A.; Reddy, V.S.; Wingard, J.R. University of Florida,
Gainesville, FL
Interferon-α (IFN-α) for maintenance therapy of multiple
myeloma increases progression free survival (PFS).
Purpose: To determine toxicity and efficacy of maintenance
IFN-α after high dose chemotherapy (HDC) and autologous pro-
genitor cell transplantation (PCT) in multiple myeloma patients.
Patients and Methods: Between 11/96 and 3/00, 33 multiple
myeloma patients received high dose chemotherapy (busulfan,
cyclophosphamide and etoposide) followed by autologous PCT.
Twenty-ﬁve of 33 patients received IFN-α maintenance therapy.
Initial IFN-α dose was 1x106 units, increased as tolerated up to
3x106 units subcutaneous three times weekly and maintained until
relapse. Reasons for not receiving IFN-α include slow hematopoi-
etic recovery (4), refusal (2), early relapse (1), and indeterminate
(1). The 25 patients receiving maintenance therapy had a median
age of 54 years, 3 in complete remission (CR), 17 with partial
response (PR), 4 with minimal response (MR), and 1 with refrac-
tory disease.
Results: The median maximum tolerated dose of IFN-α was 3 x
106 units subcutaneous three times weekly. Median duration of
IFN-α therapy was 151 days. Three patients had to discontinue
IFN-α before 30 days due to myelosuppression. An additional 8
patients had premature discontinuation (4 with myelosuppression,
1 with respiratory distress, 1 with hyperemesis, 1 with secondary
non-Hodgkin′s lymphoma, 1 switching to thalidomide). Of
patients receiving IFN-α, 5 are in CR, 9 are in PR or SD, 3 are
alive with relapsed disease and 5 have died of relapsed disease at
median follow-up of 400 days (104-1281). Two patients converted
from PR to CR. Median PFS for patients receiving IFN-α (371
days, range 104-910) was longer than that for patients not receiv-
ing IFN-α (293 days, range 70-864).
Conclusions: While there may be a benefit from maintenance
IFN-α following HDC and autologous PCT, some multiple
myeloma patients either cannot tolerate or fail maintenance
therapy. Therefore, alternative therapies need to be investigated.
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HIGH DOSE CHEMOTHERAPY FOLLOWED BY AUTOLOGOUS STEM
CELL TRANSPLANTATION IN MULTIPLE MYELOMA
Kumar, L.; Raju, G.; Prakash, N.; Singh, H.; Kochupillai, V. All India
Institute of Medical Sciences, New Delhi, India
Thirty six patients (Pts) with advanced multiple myeloma
received treatment with high dose melphalan followed by hemo-
poietic stem cell transplantation (Tx) (BM-7, PBSC-29). Pts age
ranged from 26 to 65 years (median-51.5), There were 24 males &
12 females. All pts had initially received CT,mean no of CT cycles
8.75. 20 of 36 pts had chemo-sensitive disease at the time of Tx.
The median interval from diagnosis to Tx was 10.5 (range,3-129
mon). Median no of monuclear cells infused was 4.4x10/kg (range,
2-10.4). Post-Tx,30 of 36 pts engrafted; median no of days to
engraft (ANC ≥500/cmm) was 12.5 days(range,9-24) and to
achieve platelet transfusion independence (>20,000/cmm) was 18
days (0-54). Grade III-IV oral mucositis was the major non-hema-
tologic toxicity. Post-Tx,27 of 36 pts responded;CR-23 (64%),
PR-11%. Age <50vs>50years), sex (M:F), melphalan dose (<160
mg/m2 vs >160 mg/m2 ) & myeloma type (IgG vs IgA) did not
affect the achievement of CR signiﬁcantly. CR rate was higher for
pts with chemosensitive dis.;18/20 vs 5/16, p<.01. Median dura-
tion of response has not reached yet at 17 months & is signiﬁcant-
ly longer for pts with CR, p<.01. Post Tx responding pts were
planned for maintenance therapy with interferon-alfa 3 mU three
times a week for one year. Three pts relapsed post Tx & died of
progressive.dis. at an interval of 11,22,39 mon. after Tx. Current-
ly, 27 pts are alive(22 dis.-free) at a median follow up of 17 mon.
(range,2-115 mon.). The Kaplan Meirer probability of overall sur-
vival for whole group at 60 months is 62%. Univariate analysis of
prognostic factors revealed that Hb ≤ 10g%,p<.003, hypoalbumin-
imia (≤ 3.3g%,p<.001), renal impairment(serum creatinine ≥
2mg%,p<.01)& raised B2microglobulin (p<.01) affected the sur-
vival adversely. Achievement of CR post-Tx (p<.0028) was associ-
ated with improved survival.
Conclusions: High dose melphalan followed by stem cell trans-
plantation is an effective treatment for patients with advanced
myeloma. Achievement of complete response is associated with an
improved survival.
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AUTOLOGOUS PERIPHERAL BLOOD PROGENITOR CELLS TRANS-
PLANTATION FOR THE TREATMENT OF MULTIPLE MYELOMA
Maiolino, A.; Nucci, M.; Schaffel, R.; Morgado, M.; Portugal, R.; Bia-
soli, I.; Maranhão, S.; Ferreira, J.; Figueiras, R.; Pulcheri, W. Univer-
sidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil
Objective: To assess the toxicity and the response rate of mel-
phalan (200 mg/m2) followed by autologous peripheral blood pro-
genitor cells transplantation (APBPCT) in patients with multiple
myeloma treated in a tertiary hospital in Brazil.
Design and Methods: Between February 1977 and October 2000
48 consecutive patients with multiple myeloma (45 patients), plas-
ma cell leukemia (2 patients) or amyloidosis (1 patient) were treat-
ed. De novo patients as well as those who had received prolonged
chemotherapy were admitted to transplantation. Mobilization of
peripheral blood stem cells was obtained with cyclophosphamide
1.5 g/m2 and G-CSF 10 mcg/kg/d.
Results: The median age was 52 years (range 29-66) and the
male to female ratio was 1:1. The duration of treatment before
transplantation was <18 months in 28 patients. Forty-one patients
received 3-4 cycles of VAD (vincristine, doxorubicin and dexam-
ethasone) before transplantation. The patients with plasma cell
leukemia received 2 cycles of EDAP (etoposide, dexamethasone,
cytarabine and cysplatin) before transplantation. Before transplan-
tation 25 patients were in complete remission and 18 in partial
remission. Two patients were on hemodialysis during transplant.
Febrile neutropenia and mucositis occurred in all patients. Only 1
patient (3%) died during the procedure (sepsis and multiple organ
failure). After a median follow-up time is 363 days (36-1010), 25
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patients were in complete remission, 10 in partial remission and 6
had active disease. Seven patients died due to advanced disease.
Conclusions: APBPCT with melphalan 200 mg/m2 is safe, with
low mortality rate, including older patients and those with renal
failure on hemodyalisis.
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BUSULFAN/CYCLOPHOSPHAMIDE(BU/CY)WITH STEM CELL RESCUE
FOR CHEMOTHERAPY-SENSITIVE MULTIPLE MYELOMA
Styler, M.; Topolsky, D.; Crilley, P.; Gladstone, D.; Brodsky, I. MCP
Hahnemann University Hospital, Philadelphia, PA
Twenty-six patients received a regimen of Busulfan (4mg/kg/day
X 4), Cyclophosphamide (60 mg/kg/day X 2) followed by Stem
Cell Rescue for Chemotherapy-sensitive Multiple Myeloma at
Hahnemann University Hospital between 12/11/89 and 1/12/00.
Four patients received bone marrow (BM), one patient bone mar-
row plus peripheral blood stem cells (PBSC), and the remaining
21 patients received PBSC only. The median age was 55.5 years
(range 33-70). The overall survival was 68.9% +/- 12.3% and pro-
gression free survival was 35.2% +/- 11.2% with a median follow-
up of 47.1 months(range 13 to 132.6 months). The mean time to
ANC greater than 1,000 was 8.1 days (range 6 to 14 days) and the
mean time to platelet transfusion independance was 11.4 days
(range 8-25 days). Mucositis was moderate. There was one case of
hemorrhagic cystitis which resolved with supportive care and
there were no episodes of VOD. There were no regimen related
deaths. Bu/Cy appears to be a well tolerated regimen with toxicity
and results comparable to single or tandem melphalan - based
regimens.
PEDIATRIC CANCER
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THE CONTINUUM OF CARE: IS IT SAFE FOR KIDS UNDERGOING
STEM CELL TRANSPLANTATION?
Frey, M.; Talbert, G. Duke University Medical Ctr, Durham, NC
New treatment modalities and increasing payor demands have
forced many health care providers to look at alternatives to high
cost inpatient care. Home infusion companies and home health
agencies are growing in numbers at an alarming rate. Many ther-
apies that were traditionally administered in an inpatient setting
are now being done in outpatient clinics and at home. The pur-
pose of this poster is to describe alternatives to high cost inpa-
tient care for children undergoing bone marrow and stem cell
transplantation. Alternatives to care including advances in home
infusion, outpatient treatment centers and other initiatives will be
described. The poster will also describe current and pressing
changes in the health care environment that directly impact the
care of the child undergoing stem cell and marrow transplanta-
tion. Safe and cost effective alternatives to inpatient care will be
outlined. Speciﬁc cost reduction initiatives such as the restricted
use of certain medications and treatment options will be outlined
as well as the risks and beneﬁts associated with each option. Such
options include the reduced use of IVIG, speciﬁc criteria for the
use of high cost medications such as the liposomal drugs and the
early transition of patients out of the inpatient setting will be
deﬁned.
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FEASIBILITY OF TANDEM HIGH-DOSE CHEMOTHERAPY WITH PBSC
RESCUE IN HIGH-RISK NEWLY DIAGNOSED AND RECURRENT PEDI-
ATRIC CNS TUMORS
Goldman, S.1,2; Tomita, T.1; Kletzel, M.1,2; Haut, P.R.1,2 1. Children’s
Memorial Hospital, Chicago, IL; 2. Robert H. Lurie Cancer Center,
Chicago, IL
Eight patients with high-risk newly diagnosed or recurrent
CNS tumors were treated on a tandem stem cell transplantation
trial at Children′s Memorial Hospital between 4/1998 and
7/2000. Five males and 3 females, 4-17 years of age, with the fol-
lowing diagnoses: medulloblastoma (4 with recurrence, 1 newly
diagnosed), recurrent CNS germ cell tumor (n=1), pinealoblas-
toma (n=2) were enrolled. All underwent surgery and craniospinal
radiation prior to enrollment. Prior to high dose chemotherapy
(HDC) pts underwent a minimum of two cycles of chemotherapy
with either cyclophosphamide 4.4 gm/m2/course, or carboplatin
500 mg/m2/d x 2 and VP-16 100 mg/m2/d x 3, alternating with
cyclophosphamide. PBSC were harvested following cyclophos-
phamide with G-CSF. A median of 5 harvest days (range 2-10)
were needed to collect a median of 4.0 x 108 mononuclear
cells/kg and 5.8 x 106 CD34/kg. One patient had progressive dis-
ease (pinealoblastoma) during initial therapy and was removed
from study, all others proceeded to HDC. HDC #1 consisted of
VP-16 (250 mg/m2/d x 3), Carboplatin (500 mg/m2/d x 3), and
Thiotepa (300 mg/m2/d x 3), while HDC #2 Melphalan (60
mg/m2/d x 3) and cyclophosphamide (1500 mg/m2/d x 3). Four
pts entered with NED, 3 with residual disease. Median days to
ANC >500 for PBSC rescue #1 and #2 were 11 and 10 respective-
ly. Days to platelets sustained >20K for rescue #1 and #2 were 20
and 59 respectively. One pt died on day 9 following HDC #2
with sepsis, VOD, and MSOF. Median time between HDC #1
and 2 was 27 days. Three patients did not proceed to HDC #2
due to prolonged toxicity. Four of 7 pts. obtained a CR. Four are
surviving with short follow-up. In conclusion this regimen is fea-
sible in heavily pretreated pts but toxicities are signiﬁcant. Fur-
ther enrollment and follow-up is necessary to determine efﬁcacy.
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TRANSPLANTATION OF PEDIATRIC PATIENTS WITH HIGH RISK
HEMATOLOGIC MALIGNANCIES WITH UNRELATED, HLA MIS-
MATCHED UMBILICAL CORD BLOOD
Kurtzberg, J.1; Martin, P.L.1; Howrey, R.P.1; Driscoll, T.A.1; Szabolcs,
P.M.1; Ciocci, G.1; Stevens, C.E.2; Rubinstein, P.2 1. Duke University
Medical Center, Durham, NC; 2. New York Blood Center, New York, NY
Over the past decade, HLA-mismatched, unrelated umbilical cord
blood (UCB) has been increasingly used as a source of hematopoietic
stem cells for patients who lack a conventional bone marrow donor.
Between 8/93 and 9/2000, the Pediatric BMT Program at Duke has
transplanted 132 consecutive children (<18 years) with high risk
malignancies with 0-3 antigen mismatched UCB grafts. The median
patient age was 8.6 years (range 0.3-17), median weight 32.1kg (range
4-118), 43% were female, 49 % were CMV seropositive, 30% were
minorities. 69 patients had ALL: 15 T-ALL, 14 Infant ALL, and 41
B-Precursor ALL in ﬁrst (n=9), second or greater remission (n=38) or
relapse (n=22). Thirty-eight patients had ANLL in ﬁrst (n=4), 2nd or
subsequent remission (n=6)or relapse (n=28). Eight patients had
CML (2 in 1st chronic phase) and 3 had JCML. Of the remaining
patients,11 had MDS and 3 had recurrent advanced stage NHL. All
but 5% of grafts were 1-3 antigen mismatches with the recipients
(28%- 1 and 65%- 2 antigen mismatches). The median nucleated cell
dose/kg was 4.3x107 and median CD34 cell dose 2.9x105/kg. 33% of
the patients were prepared for transplant with chemotherapy alone
while the remaining patients received TBI-based regimens. GvHD
prophylaxis was CSA/steroids and all patients received G-CSF from
day 0. 94% of patients engrafted neutrophils in a median of 26 days.
The median days to achieve a platelet count of 50,000/µL and RBC
transfusion independence were 81 and 52, respectively. 38% of
patients experienced moderate to severe acute GvHD while 8%
developed limited cGvHD. 50% of patients surviving a median of 2
years, 48% event-free. The major cause of death was infection in the
ﬁrst 100 days post transplant. Leukemic relapse occured in 18% of
patients. We conclude that mismatched UCB should be strongly
considered for children in need of transplantation therapy.
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BUSULFAN DOSING FOR CHILDREN < 2 YEARS OLD UNDERGOING
STEM CELL TRANSPLANTATION
Martin, P.L.; Howrey, R.P.; Driscoll, T.; Szabolcs, P.; Allison-Thacker,
J.; Kurtzberg, J.; Petros, W.P. Duke University Medical Center,
Durham, NC
Ablative chemotherapy regimens for young children often use
Busulfan instead of radiation therapy. Although, dosing guidelines
for older children are well established, guidelines for children
under 2 years are lacking. We have treated 121 children under the
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age of 2 years with Busulfan as part of their ablative regimen.
Pharmocokinetic data, including steady state plasma concentration
(CSS), AUC and apparent plasma clearance normalized to
patient′s body surface area (NAP Cl/f) was available on 53 patients
from a single onsite laboratory. The median age of these 53
patients was 8.6 months with a range of 2 weeks to 24 months.
Fourteen of the patients had malignant disease and 39 had non-
malignant disease. The table below summarizes the PK data.
Using a target of 600 − 900 ng/mL for the CSS, 4 of the 6
patients receiving 20 mg/m2 required a dose reduction, 1 required
a dose escalation and 1 needed no changes. For the 29 patients
receiving 30 mg/m2, 6 required a dose reduction, 11 required a
dose escalation and 12 needed no changes. For the 18 patients
receiving 40 mg/m2, 14 required a dose reduction, none required a
dose escalation and 4 needed no changes.
Our current guideline is to use 20 mg/m2 dosing for patients
between 0 and 3 months, 30 mg/m2 for the age range of >3
months to 2 years, 40 mg/m2 for the age range of >2 years to 6
years and 1 mg/kg/dose for ages ≥6 years. Relationships to
engraftment, toxicity and survival data will be presented.
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NEW TREATMENT MODALITIES IN METASTATIC NEUROBLASTOMA:
THE USE OF MIBG (METAIODOBENZYLGUANIDINE)WITH AUTOLO-
GOUS BONE MARROW TRANSPLANTATION
Talbert, G.; Frey, M.A. Duke University Medical Ctr, Durham, NC
Long term survival rates for children with metastatic neuroblas-
toma are poor, even with high-dose chemotherapy and autologous
bone marrow transplantation. The poor prognosis associated with
this disease has led to a search for new treatment modalities that
will improve both morbidity and mortality. One such treatment
option is the use of Metaiodobenzylguanidine (MIBG) with a sub-
sequent autologous bone marrow rescue. MIBG is a guanethidine
derivative with a structure analogous to norepinephrine, which
permits selective concentration in the sympathic nervous system.
Because of this specificity, MIBG is now being studied in the
detection and treatment of neuroblastoma. MIBG is administered
intravenously. Due to the radioactivity of this agent, patients
should ideally be placed in a lead lined room during the infustion
and remain there until cleared by radiation safety (often 3-4 days).
Use of MIBG in the adult patients has been well documented.
Treatment of the pediatric patient with this highly radioactive
material remains a challenge. Small children must be placed in a
lead lined room with minimal adult supervision and nursing care.
These children require antiemetics, hydration and sedation. The
Pediatric Stem Cell Program at Duke is one center that is study-
ing the use of MIBG with autologous bone marrow rescue in the
children. The purpose of this abstract is to:
1. Deﬁne the mechanism, rationale and current status of MIBG
therapy in neuroblastoma patients.
2. Identify the unique challenges that pediatric patients face
while receiving MIBG in a lead lined room.
3. Describe nursing strategies to care for these patients for the
duration of the therapy.
The use of MIBG with autologous bone marrow rescue has the
potential to improve long term survival rates of children with
metastatic neuroblastoma. Care of these children requires a well-
defined plan. This abstract will illustrate how to safely provide
care to the child receiving MIBG therapy.
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AMPHOTERICIN B LIPID COMPLEX (ABLC) USE IN PEDIATRIC STEM
CELL TRANSPLANTATION (SCT)
Wiley, J.M.1; Matera, J.A.2 1. Sinai Hospital, Baltimore, MD; 2.
Liposome, Princeton, NJ
Background: Invasive fungal infections (IFI) remain a signiﬁcant
cause of morbidity and mortality in pediatric recipients of stem
cell transplantation. For recipients who develop proven or pre-
sumed infections Amphotericin B Desoxycholate (AmB) has been
the standard treatment of choice. In patients where infections are
resistant to standard AmB or who develop intolerant renal toxicity
survival has been poor. The use of lipid complex AmB provides a
safer, effective alternative.
Methods: We have previously reported the use of ABLC in 530
pediatric patients with IFI treated for proven or presumed disease
and intolerant or resistant to AmB. Patients were indentiﬁed from
the CLEAR (Collaborative Exchange of Antifungal Research)
database where data were collected in a Phase IV fashion.
Results: We now report this experience in a cohort of 203
patients who are recipients of allogeneic (n=178) or autologous
(n=25) stem cell transplantation. Patients were under age 20 and
were treated with ABLC for a median duration of 16 days at a
median dose of 5.0 mg/kg/d. A total of 80 infections were indenti-
ﬁed (yeast=53, molds=27). Median baseline and end of treatment
serum creatinine values were 0.9 mg/dL and 1.1mg/dL, respec-
tively. Response rates for evaluable patients were 30% (CR+PR)
and 64% (CR+PR+SD). The response rates for yeast (43%) and
molds (40%) were similar. A total of 9 (4.5%) patients required
new dialysis during ABLC treatment. Only the recipients aged 12-
20 had a signiﬁcant rise in creatinine (1.2 to 1.6 mg/dL).
Conclusion: These data demonstrate that ABLC is a safe and
effective therapy for pediatric SCT recipients with proven or pre-
sumed IFI even in the case of AmB failures.
QUALITY OF LIFE
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CHANGES OF QUALITY OF LIFE DURING THE PERIOD OF TREAT-
MENTS IN PATIENTS WITH HIGH RISK BREAST CANCER
Park, E.; Lee, E. Samsung Medical Center, Seoul, South Korea
High risk breast cancer patients receive aggressive treatments
such as APBSCT in order to prevent the recurrence. These treat-
ments take a long time and decrease the quality of life of patients
as a result. The purpose of this study is to examine when the
changes of quality of life are dramatic in general and in speciﬁc
dimension. This is a time series study of two types of treatment
groups, in which 15 patients were treated by chemotherapy only
and nine patients by auto-peripheral blood stem cell transplanta-
tion. Subjects were in this study were stage III and above of breast
cancer.
Data were collected from April 1999 to April 2000 with the 3
month-interval starting after 3rd cycle of chemotherapy. Data were
collected 3 times; treatment period, treatment ﬁnishing period and
3 months later after the treatment.
Ferrell’s QOL instrument was used which had been developed
for the breast cancer patients in 1989. As a result, average age was
43.29 years (± 4.38yrs) and the number of married person was
22(91.7%). Scores of quality of life were 5.45 at 1st period after
3rd cycle of chemotherapy, 5.17 after treatment, 5.10 at 3 months
later after treatment and difference of quality of life was decreased
according to period of treatment (P=.085). Only the psychological
dimension of the quality of life showed the signiﬁcant difference
(P=.045). Two different treatment groups showed a difference of
quality of life at 3month later after treatment.
In conclusions, high risk breast cancer patients showed the
decreased quality of life related to treatment up to 3 months later
of treatment. Subjects who received APBSCT returned to the
normal quality of life more rapidly than those who received
chemotherapy. Psychological nursing intervention was needed
during the whole period of treatment.
